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ABSTRACT 
Amy L. Bracken 
 
EFFECTS OF NICOTINE EXPOSURE IN ADOLESCENT RATS ON 
ACQUISITION OF ALCOHOL DRINKING AND RESPONSE TO NICOTINE  
IN ADULTHOOD 
 
 Nicotine is one of the most widely abused drugs in the world, and most 
smokers begin smoking during their adolescent years.  Adolescence is a unique 
developmental period during which vulnerability to the effects of drug exposure is 
especially high.  This dissertation uses rodent models to investigate the 
persistent effects of adolescent nicotine exposure on both neurobiological and 
behavioral measures of drug sensitivity in adulthood.  The aims of this 
dissertation were to 1) determine whether nicotine would be self-administered 
into the posterior ventral tegmental area (pVTA), a neuroanatomical component 
of the mesolimbic dopamine (DA) system, which is known to be involved in 
reward and reinforcement; 2) investigate whether adolescent nicotine exposure 
would alter the sensitivity of the mesolimbic DA system as measured by DA 
release in the nucleus accumbens (NAc) in response to nicotine microinjections 
into the pVTA; 3) examine the effects of adolescent nicotine exposure on 
behavioral sensitization to nicotine in adulthood; and 4) investigate whether 
adulthood alcohol drinking behavior, in both Wistar and alcohol-preferring (P) 
rats, would be augmented by nicotine exposure during adolescence.  Results of 
this dissertation demonstrated that 1) the pVTA is a neuroanatomical site that 
 vi 
supports nicotine self-administration; and that adolescent nicotine exposure 
results in 2) increased nicotine-stimulated DA release in the NAc during 
adulthood; 3) augmented behavioral sensitization to nicotine in adult animals; 
and 4) enhanced acquisition of alcohol drinking behavior in adult Wistar and P 
rats.  Overall, this dissertation provides insight into the diverse and persistent 
changes, in both neurobiology and behavior, caused by exposure to nicotine 
during the critical developmental period of adolescence.  
 
       
 
William J. McBride, PhD., Chair 
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I.  INTRODUCTION  
 
A.  Nicotine and nicotinic receptors 
 
Drug addiction is a worldwide problem that carries high monetary and 
societal costs.  Tobacco is one of the world’s most widely-abused drugs.  Here in 
the United States, cigarette smoking is the leading cause of preventable disease, 
disability, and death (NIDA 2006).  It is estimated that 30% of the U.S. population 
over age 12 are regular smokers (SAMHSA 2003).  Smoking use increases risk 
of cancer, cardiovascular disease, and stroke.  Worldwide, only malaria is 
responsible for more deaths than smoking (Mansvelder and McGehee 2002).   
Tobacco contains thousands of chemicals.  Of these, nicotine is the 
primary psychoactive ingredient.  It occurs naturally in the tobacco plant, the 
leaves of which have been used for medicinal and recreational purposes for 
thousands of years.  Tobacco is most commonly smoked, but can also be 
absorbed through the membranes inside the mouth in the form of smokeless 
tobacco.  More recently, nicotine chewing gum and transdermal nicotine patches 
have been marketed primarily to aid in smoking cessation. 
 Once in the bloodstream, nicotine flows throughout the body and readily 
crosses the blood-brain barrier.  It reaches the brain within 60 seconds, at an 
initial concentration of 100-500 nM in the blood and brain (Karan et al. 2003).  Its 
primary site of action is the nicotinic acetylcholine receptor (nAChR).  nAChRs 
are membrane-bound ligand-gated ion channels distributed widely both 
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peripherally, at the neuromuscular junctions of somatic muscles, and in the 
central nervous system (CNS), in the autonomic ganglia and throughout the 
brain.  Nicotine activates nAChRs in the CNS to elicit its psychoactive effects, 
which include increased arousal, muscle relaxation, decreased anxiety, and 
mood elevation. 
Because of their prevalence throughout the body, nAChRs have been 
widely studied (reviews by Vidal 1996; Changeux et al. 1998; Leonard and 
Bertrand 2001; Mansvelder and McGehee 2002).  The nAChR is made up of five 
subunits, arranged symmetrically around a central pore.  Genes for ten different 
α subunits and four different β subunits have been identified, although the most 
prevalent receptors in the mammalian CNS contain either a combination of α4 
and β2 subunits, or they are α7 homomers (Jones et al. 1999).  When 
acetylcholine (ACh), the endogenous ligand and neurotransmitter, or nicotine, an 
exogenous nAChR agonist, binds to the receptor on an α subunit near the N 
terminus, a conformation change increases the probability that cations will pass 
through the central pore.  Typically, sodium (Na+) ions enter the cell and 
potassium (K+) ions exit, with the net result being an inward flow of positively 
charged ions.  This excites the cell and can lead to action potential firing.  In 
some neuronal nAChRs, calcium (Ca2+) ions can also flow into the cell, which 
means that nAChR activity could influence Ca2+-dependent processes such as 
ion pumps and neurotransmitter release (Wonnacott 1997). 
nAChRs are distributed widely throughout the brain, including in the 
brainstem and cerebellum, the midbrain, the hippocampus and other limbic 
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areas, the olfactory bulbs, the prefrontal cortex, and throughout the different cell 
layers of the cortex (Tribollet et al. 2004).  They can be found on cell bodies and 
dendrites, where they may modulate postsynaptic effects, or on axon terminals, 
where they can modulate synaptic transmission. The α4β2-containing 
heteromeric and α7 homomeric receptors were identified early on in the study of 
nAChRs and differentiated by their different affinities for nicotine binding 
(Changeux et al. 1998).  The α4β2 receptors have a high affinity for nicotine, and 
the α7 receptors are low-affinity nicotine binding sites.  Equally important are the 
desensitization properties of these two receptor subtypes; at nicotine 
concentrations similar to those experienced by smokers, both the α4β2 and α7 
nAChRs are activated, but the α4β2 nAChRs are desensitize within minutes 
(Mansvelder and McGehee 2002).  The α7 nAChRs require higher nicotine 
concentrations to become desensitized, and they are slower to do it.  Therefore, 
when studying nicotinic modulation of neuronal pathways, both the activation and 
desensitization patterns must be considered. 
 
B.  Nicotine and the mesolimbic dopamine system 
 
Because nAChRs are widely distributed throughout the brain, it is possible 
that nicotine acts on many different cellular processes that are either directly or 
indirectly related to the process of reward and the development of drug addiction. 
However, a wide breadth of research has led to the conclusion that dopamine 
(DA) is the neurotransmitter that plays the major role in the behavioral stimulus 
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properties of nicotine (reviewed by Stolerman and Shoaib 1991; Dani and 
Heinemann 1996; Di Chiara 2000; Balfour 2004).   
The intracranial self-administration (ICSA) technique has been used to 
identify discrete brain regions involved in the initiation of response-contingent 
behaviors for the delivery of a reinforcer (Bozarth and Wise 1980; Goeders and 
Smith 1987; McBride et al. 1999).  Previous research using the ICSA procedure 
in rodents has demonstrated central nervous system sites where drugs of abuse 
such as ethanol (Gatto et al. 1994; Rodd-Henricks et al. 2000a), amphetamine 
(Hoebel et al. 1983), and cocaine (Goeders and Smith 1983, 1986; McKinzie et 
al. 1999) are self-infused.  The rewarding properties of nicotine have been linked 
to the drug’s ability to stimulate the mesolimbic DA system (Di Chiara 2000), 
similar to many other drugs of abuse (Wise and Bozarth 1987; Robinson and 
Berridge 1993).  The major neuronal pathway in this system originates in the 
ventral tegmental area (VTA) and projects to the nucleus accumbens (NAc) as 
well as limbic structures and the prefrontal cortex. 
There is much evidence to support a role for this pathway in the 
reinforcing effects of nicotine, which could be related to the development of 
nicotine addiction.  First, receptor binding studies have shown that nAChRs are 
highly localized in the VTA compared to surrounding areas (Klink et al. 2001; 
Wooltorton et al. 2003).  Behavioral studies have also lent support.  Clarke and 
colleagues (1988) knew that other psychomotor stimulants such as cocaine and 
amphetamine activated the mesolimbic DA system to exert both their behavioral 
stimulating and reinforcing actions.  By using local microinjections of 6-
 5 
hydroxydopamine (6-OHDA) into the NAc to selectively deplete DA terminals in 
rats and observing a subsequent decrease in locomotor response to nicotine 
injections, Clarke and colleagues were able to determine that nicotine’s 
locomotor stimulant effects were also predicated on activation of the mesolimbic 
DA system.  Nicotine injections directly into the VTA have been shown to 
increase locomotor activity in rats (Panagis et al. 1996).  Repeated intra-VTA 
microinjections of the nicotinic receptor agonist cytisine also resulted in 
locomotor sensitization, further indicating that nAChRs within the VTA can 
produce locomotor effects (Museo and Wise 1994).   
Corrigall and colleagues used DA receptor antagonists and site-specific 6-
OHDA lesion techniques to investigate the role of DA in nicotine self-
administration behavior (Corrigall and Coen 1991; Corrigall et al. 1992).  They 
observed that systemic injections of both DA D1 and D2 receptor antagonists 
reduced intravenous (i.v.) nicotine self-administration, and that this reduction was 
not due to overall motor impairment.  Corrigall and colleagues also concluded 
that DA release in the NAc was essential for nicotine self-administration, as the 
bilateral lesions of DA terminals in this area significantly reduced responding for 
i.v. nicotine.  Later, Corrigall’s group shed even more light on the specific site of 
action of nicotine when they demonstrated that infusions of the α4β2-selective 
nAChR antagonist dihydro-β-erythroidine (DHBE) directly into the VTA 
attenuated i.v. nicotine self-administration (Corrigall et al. 1994).  DHBE did not, 
however, cause similar reductions in operant responding for food or cocaine, or 
in overall locomotor activity.  Intra-VTA nicotine was also shown to induce 
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conditioned place preference, which is yet another indication that nicotine is 
rewarding within the VTA (Laviolette and van der Kooy 2003b).  Finally, intra-
VTA nicotine perfusion increased DA levels in the NAc, and this increase was 
potentiated when the rats were pretreated with systemic nicotine for 5 days 
preceding the microdialysis study (Rahman et al. 2004).  Taken together, all of 
these studies indicate that the VTA is a specific site of action within the 
mesolimbic DA system at which nicotine exerts its motivational stimulus effects. 
While these studies and many more have concluded that nicotine acts 
directly on DA neurons in the VTA to exert its excitatory effects, there are other 
cell types within the VTA that also express nAChRs (Klink et al. 2001).  
Specifically, GABA interneurons and glutamatergic presynaptic terminals both 
synapse onto DA neurons in the VTA and express nAChRs.  Studies on the 
subunit compositions of the different VTA nAChRs have revealed that the DA 
and GABA neurons express mostly non-α7, and therefore high-affinity and fast-
desensitizing, nAChRs (Pidoplichko et al. 1997; Klink et al. 2001).  Conversely, 
glutamatergic neurons originating in the prefrontal cortex express presynaptic 
nAChRs in the VTA which are mostly α7-containing, and therefore low-affinity 
and slower to desensitize (Kalivas et al. 1989).  Mansvelder and colleagues 
proposed two synaptic mechanisms by which all three neuron types in the VTA 
may contribute to long-lasting changes in mesolimbic DA activity and thus 
development of nicotine addiction (Mansvelder and McGehee 2000; Mansvelder 
et al. 2002).   
 7 
Since nAChRs are present both on DA neurons and glutamatergic 
terminals in the VTA, nicotine activates the DA neurons both directly at nAChRs 
and through the release of glutamate into the synapse and its activation of 
postsynaptic NMDA receptors (Bonci and Malenka 1999).  The depolarization 
induced by nAChR activation would remove the magnesium block on the NMDA 
receptor, and allow glutamate to bind to the receptor and Ca2+ ions to enter the 
cell.  Together, this pre- and post-synaptic activation of the cell can induce long-
term potentiation (LTP).  And while the nAChRs on the DA neurons are mostly 
the non-α7 type and therefore subject to quick desensitization, the α7 nAChRs 
on the glutamatergic terminals resist desensitization and therefore allow for 
continued activation of the DA neurons via NMDA receptors (Mansvelder and 
McGehee 2002).  Thus, LTP of VTA DA neurons could be involved in elevated 
DA release in the NAc.  Notably, Mansvelder and McGehee (2000) demonstrated 
that such LTP could be induced by nicotine concentrations comparable to that of 
human cigarette smokers after just one cigarette. 
GABA interneurons in the VTA also play a role in nicotine’s actions on the 
mesolimbic DA system.  Nicotine binds to the nAChRs on these interneurons, 
resulting in a transient increase in inhibitory GABA input to the DA neurons.  
Since most of the nAChRs on the GABA interneurons are of the non-α7 variety, 
they desensitize rapidly and reduce the short-lived inhibitory control on the DA 
neurons.  This was also shown to take place in the presence of low nicotine 
concentrations, similar to those achieved by smokers (Mansvelder and McGehee 
2002).  Thus, the DA neuron excitement and the glutamate-driven LTP 
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mentioned above are facilitated by a reduction in inhibitory GABAergic tone.  
Together, these three types of nAChR-expressing neurons in the VTA promote 
nicotine-induced DA release in the NAc and, over time, can change the way the 
mesolimbic pathway responds to nicotine which can lead to nicotine addiction. 
In addition to the VTA, other brain areas have been identified as possible 
sites of action of nicotine in relation to rewarding effects.  Accumbal DA levels 
are elevated when nicotine is infused directly into the NAc itself, but this effect is 
transient compared to nicotine infusions into the VTA (Nisell et al. 1994b).  The 
pedunculopontine tegmental nucleus (PPTg) has also been identified as a site of 
action for nicotine; specifically, cholinergic neurons projecting from the PPTg to 
the VTA DA neurons are activated during systemic nicotine self-administration, 
and lesions of these neurons reduce self-administration behavior (Lanca et al. 
2000).  However, both of these sites of action seem to result in input to VTA DA 
neurons, so this seems to be the consensus primary action site for the reinforcing 
effects of nicotine.    
  
C. Nicotine and ethanol interactions 
 
 Often, drug addicts will co-abuse two or more different drugs.  Nicotine 
and ethanol (EtOH) are two of the most highly co-abused drugs in the world.  In 
the United States, it is estimated that 90% of alcoholics are smokers, compared 
with just 30% of the general population (Daeppen et al. 2000).  Similarly, 
alcoholism is estimated to be 10-14 times more common among smokers than 
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non-smokers (DiFranza and Guerrera 1990).  The amount of tobacco smoked is 
positively correlated with alcohol intake and the severity of alcohol dependence 
(Grant et al. 2004). 
 Due to the high rate of nicotine and EtOH co-abuse in humans, significant 
research has been directed at elucidating the interactions of these two drugs in 
laboratory animals.  Nicotine’s locomotor-activating effects were enhanced when 
EtOH was co-administered, even though EtOH alone decreased locomotor 
activity (Schaefer and Michael 1992).  Home-cage EtOH drinking was increased 
in rats during chronic nicotine treatment, and persisted even one week after 
cessation of nicotine exposure (Pothoff et al. 1983; Blomqvist et al. 1996).  
Conflicting results have emerged from studies investigating the effects of chronic 
nicotine treatment on operant responding for EtOH in rats, with some data 
demonstrating an increase in EtOH self-administration (Le et al. 2000; Clark et al. 
2001) whereas one study demonstrated a decrease (Sharpe and Samson 2002).  
Nicotine has been shown to reinstate EtOH seeking in rats following extinction of 
operant responding (Le et al. 2003; Lopez-Moreno et al. 2004).  Although any 
divergent results could be due to differences in nicotine administration (repeated 
injections vs. continuous infusion) and/or rat strain, it is clear that the 
underpinnings of nicotine/EtOH interactions are complex. 
In addition to investigation of systemic effects, research has also been 
aimed at elucidating the neuroanatomical sites regulating nicotine and EtOH 
interactions.  Several studies have indicated a role for VTA nAChRs in the 
actions of EtOH, including EtOH-stimulated NAc DA release and EtOH-
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stimulated locomotor activation (Larsson et al. 2002).  In vivo microdialysis has 
been used to demonstrate that the noncompetitive nAChR antagonist 
mecamylamine blocked the EtOH-stimulated rise in NAc DA (Blomqvist et al. 
1993).  However, all drugs in this experiment were administered systemically, 
which makes the effects on specific brain regions difficult to differentiate.  Later, 
this same group followed up on these results using site-specific techniques, and 
determined that local infusion of mecamylamine into the VTA blocked the rise in 
NAc DA induced by EtOH reverse microdialysis into the NAc (Ericson et al. 
2008).  However, the specific regions mediating EtOH-stimulated NAc DA 
release implicated by this group differ from the regions implicated by our 
laboratory.  Ericson’s group argues that EtOH infusion into neither the aVTA nor 
the pVTA results in NAc DA release; rather, the NAc itself is the primary site of 
action of EtOH in the mesolimbic DA system, whereas the VTA is a secondary 
site in a NAc-VTA-NAc signaling loop.  Additionally, their 2008 study indicated 
that nAChRs in the anterior VTA (aVTA), but not posterior VTA (pVTA), were 
involved in mediating NAc DA release.  Our laboratory has shown that rats self-
administer EtOH into the pVTA but not the aVTA (Rodd-Henricks et al. 2000a) 
and that EtOH microinjections into the pVTA stimulate DA release in the NAc 
(Ding et al. 2009; Rodd et al. 2007).  So, while there is disagreement about the 
primary site of action of EtOH within this system, one can conclude that nAChRs 
are likely involved in the actions of EtOH in some capacity. 
The nAChR subtypes mediating certain effects of EtOH have been 
investigated.  Systemic pretreatment of either DHBE, which is selective for α4β2 
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nAChRs, or methyllycaconitine (MLA), which is selective for α7 nAChRs, failed to 
reduce both EtOH-stimluated locomotor activity and EtOH-induced DA overflow 
in the NAc in mice (Larsson et al. 2002).  However, the less selective negative 
allosteric nAChR modulator mecamylamine did block both of these EtOH-
stimulated effects, so it appears that EtOH may not act on these nAChR 
subtypes.  
nAChRs have also been implicated in the self-administration of EtOH.  
Daily nicotine injections (0.8 mg/kg) were shown to increase EtOH consumption 
after repeated treatment, following an initial suppression of EtOH drinking on the 
first day (Le et al. 2000).  Systemic injections of the nAChR antagonist 
mecamylamine reduced EtOH intake.  Together, these results suggest that 
activation of nAChRs are involved in EtOH consumption behavior.  Furthermore, 
systemic injections of the competitive nAChR antagonist DHBE, which is 
selective for α4β2 nAChRs, did not reduce EtOH intake (Le et al. 2000), which 
indicates that this receptor subtype is not involved in EtOH consumption 
behavior.  A related study was conducted by administering mecamylamine 
directly into the VTA using reverse microdialysis, and assessing its effects of 
EtOH drinking as well as NAc DA release (Ericson et al. 1998).  Their findings, 
consistent with the study from Le and colleagues, were that a single 
mecamylamine infusion in the VTA reduced EtOH intake and preference for 




D.  The alcohol-preferring P rat 
 
 A useful genetic tool for studying EtOH-related behaviors in the laboratory 
is the alcohol-preferring P rat.  This selectively-bred line of rats voluntarily 
consumes an average of 5-8 g/kg body weight/day of EtOH and meets the 
criteria proposed for an animal model of alcoholism (Lumeng et al. 1977; Cicero 
1979; McMillin 1997; Murphy et al. 2002).  However, there is evidence that they 
may show differential sensitivity to other drugs of abuse as well, as compared to 
alcohol-non-preferring NP rats.  Adult P rats are less sensitive to the locomotor 
activating effects of amphetamine (McKinzie et al. 2002), but more sensitive to 
locomotor activation by nicotine (Gordon et al. 1993).  Importantly for this 
dissertation, P rats also self-administer higher levels of intravenous nicotine than 
NP rats, and were more susceptible to relapse of nicotine self-administration 
behavior (Le et al. 2006).  Studies on different lines of rats selectively bred for 
high and low EtOH intake, the Alko Alcohol (AA) and Alko Non-Alcohol (ANA) 
rats, did not reveal any differential effects of nicotine on locomotor sensitization 
or DA release in the NAc (Kiianmaa et al. 2000).  However, P rats have been 
shown to abuse nicotine, as measured by self-administration and relapse 
following a period of deprivation (Le et al. 2006), in addition to being considered 
an animal model of alcohol abuse.  Thus, the P and NP rats are likely a more 
appropriate genetic model of alcoholism than the AA and ANA rats in which to 
test the effects of nicotine. 
  
 13 
E.  Adolescence: a critical neurobiological time period 
  
Adolescence is a unique developmental period that is characterized by 
landmarks such as physical growth, behavioral maturation, and neuronal 
development.  Behaviorally, adolescence is also the time when novelty- and 
sensation-seeking emerge, which, in both humans and laboratory animals, has 
been associated with drug use (Martin et al. 2002; Cain et al. 2005). 
 The National Institute of Drug Abuse 2005 Monitoring the Future Study 
indicates that among 12th graders surveyed, 74% had used alcohol, 50% had 
smoked cigarettes, and 45% had smoked marijuana (NIDA 2006).  While some 
experimentation with drugs appears to be the norm during adolescence, it has 
been shown that early onset of alcohol and drug use is a predictor of later alcohol 
and drug abuse and dependence (Yamaguchi and Kandel 1984; Anthony and 
Petronis 1995; Chen et al. 2009).   
 Adolescence is the period during which most human smokers initiate drug 
use.  The deleterious effects on the individual and the high healthcare costs of 
smoking are well known.  Of particular concern is initiation of tobacco use during 
the teenage years, which can result in long-term consequences including an 
increased risk for progression to use of other illegal drugs (Kandel et al. 1992), 
as well as a higher risk of development of alcohol dependence (John et al. 2003), 
and a decreased probability of smoking cessation (Chen and Millar 1998).  Data 
indicate that the vast majority of smokers subject themselves to these additional 
risks, because approximately 90% of cigarette smokers begin smoking before the 
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age of 18 (CDC 2007).  Children of smokers may be involuntarily exposed to 
environmental tobacco smoke (ETS) in their homes.  This is also a public health 
concern, because in addition to the acute health effects of ETS, childhood ETS 
exposure has been correlated with significantly higher rates of adulthood 
smoking (Larsson et al. 2001). 
 Research has demonstrated that adolescents are more sensitive to some 
drug effects and less sensitive to others, but a consistent theme in the literature 
is that adolescent brains respond differently to drugs of abuse than those of 
adults (reviewed by Spear, 2000).  An underlying cause of differential drug 
sensitivity during adolescence could be the extensive neuronal development and 
maturation that take place in the forebrain during this time.  A vast amount of 
synaptic pruning takes place during adolescence, following the overproduction of 
synaptic connections during prenatal and neonatal time periods.  The presumed 
purpose of this developmental plasticity is to allow neural networks to form in a 
way as to best accommodate environmental needs.  Thus, it is plausible that 
drugs used during this time could result in neurobiological changes, and that 
those changes might persist well into adulthood.   
Studies in animals have identified specific changes that occur during 
adolescence in brain regions important for reward and behavioral reinforcement, 
including the mesolimbic DA system.  Specifically, the density of dopaminergic 
fibers projecting to the prefrontal cortex (PFC) and striatum increase until 60 
days of age in rats, at which time adult levels are reached (Kalsbeek et al. 1988).  
Additionally, D1 and D2 receptor levels in the PFC and striatum peak during 
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adolescence before declining into adulthood (Tarazi and Baldessarini 2000).  D1 
and D2 receptor binding also peaks in the NAc during adolescence, before 
declining by about one-third by 60 days of age.  Activation of these receptors and 
neurons could also have downstream consequences which may undergo 
changes during adolescence.  For example, stimulatory (D1 receptor) and 
inhibitory (D2 receptor) effects on adenylyl cyclase (AC) in the NAc were 
attenuated in adolescence, as compared to adulthood, in rats.  Together, these 
findings indicate that adolescence is likely a peak time for dopaminergic activity 
in brain regions important for reward, and these regions might thus be 
susceptible to drug-induced alterations. 
 
F.  Adolescence and nicotine 
 
Overall, studies in rodents have indicated that adolescent rats are more 
sensitive to the rewarding effects of nicotine than adults (reviewed by Slotkin, 
2002).  Low doses of nicotine induced place preference conditioning in 
adolescent rats but not adult rats (Vastola et al. 2002; Belluzzi et al. 2004).  
Cross-sensitization has also been reported; adolescent rats treated with nicotine 
showed an increased locomotor elevation in response to amphetamine 
administration, whereas adult rats did not under similar study conditions (Collins 
et al. 2004a).  Additionally, adolescent rats have been shown to intravenously 
self-administer a greater number of infusions of nicotine than their adult 
counterparts over a 4-week self-administration paradigm (Levin et al. 2003). 
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In animal studies, adolescent exposure to nicotine has been shown to 
produce behavioral effects that last into adulthood, such as anxiety-like behavior 
and changes in fear conditioning in rats (Slawecki et al. 2003; Smith et al. 2006).  
Adolescent nicotine treatment has also resulted in an increased propensity for 
rats to self-administer nicotine during adulthood.  Adult rats intravenously self-
administered more nicotine following peri-adolescent pretreatment with nicotine 
than with no pretreatment.  These lasting effects of nicotine seem to be specific 
to exposure during the adolescent time period, as equivalent exposure during 
adulthood did not result in similar behavioral changes (Adriani et al. 2003). 
 Faraday et al. (2003) demonstrated that chronic nicotine treatment had 
both acute and long-lasting motor activity increasing effects in adolescent rats, 
which were distinct from the effects observed when the rats were pretreated with 
nicotine during adulthood.  However, shortcomings of this study included the lack 
of a cross-wise study design, which would have allowed for examination of 
within-subject effects of different adolescent and adult treatments.  Additionally, 
the adolescent nicotine exposure occurred in the behavioral testing apparatus, 
which did not allow for analysis of effects of adolescent nicotine treatment on 
subsequent novel environment responding to be studied.  However, together with 
the knowledge that the locomotor activating properties of nicotine are predicated 
on mesolimbic DA release (Clarke et al. 1988), the results of the Faraday et al. 
(2003) study indicate that the same neurobiological substrates that underlie 
nicotine-induced locomotor activation may also underlie nicotine reward 
sensitivity. 
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 Previous work demonstrated that nAChR levels are up-regulated in 
midbrain areas implicated in nicotine reward and dependence, including the VTA, 
in adult rats following adolescent treatment with nicotine (Trauth et al. 1999; 
Abreu-Villaca et al. 2003; Adriani et al. 2003).  The VTA is an essential neural 
substrate for EtOH self-administration, as evidenced by Rodd-Henricks and 
colleagues’ work (2000a) demonstrating intracranial self-administration of EtOH 
into the pVTA but not areas surrounding the pVTA in Wistar rats.  Given that 
nAChRs have been implicated for their involvement in EtOH self-administration 
by Le and colleagues (2000), it is possible that adolescent-nicotine-induced 
changes in nAChRs may influence EtOH drinking both acutely and later in life. 
Mechanisms underlying nicotine and EtOH co-abuse have also been 
investigated in adolescent animal models.  Only two previous studies have 
focused on EtOH drinking following adolescent nicotine exposure.  One, by Smith 
and colleagues (2002), concluded that adulthood EtOH drinking was not affected 
by peri-adolescent nicotine exposure in Sprague-Dawley rats, a non-selected 
line.  A more recent published study used alcohol-preferring AA rats to study the 
effects of adolescent nicotine exposure on adulthood EtOH intake (Kemppainen 
et al. 2009).  That study also concluded that adulthood EtOH intake was 
unaffected by adolescent nicotine exposure.  However, AA rats are not well-
characterized in terms of EtOH intake or seeking, or relapse-like behavior 
following deprivation of EtOH, in contrast to the P rats used in our laboratory.  
Even though these two studies concluded that adolescent nicotine exposure did 
not affect EtOH drinking in adulthood, the fact that teenage smoking is 
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associated with a greater risk of EtOH and other drug abuse in adulthood points 
toward a common underlying mechanism, and calls for further study into the 
topic. 
One additional consideration is the number of other components of 
tobacco smoke.  There are thousands of chemicals in cigarette smoke, and one 
or more of them may act on biological systems.  For example, acetaldehyde, 
which is a major metabolite of EtOH within the brain, is a component of cigarette 
smoke.  So, exposure to the additional chemicals in smoke, in addition to the 
nicotine itself, may play a role in the link between adolescent smoking and 
adulthood EtOH drinking. 
 
G.  Hypotheses and specific aims 
  
Previous research has indicated that activation of the mesolimbic 
dopamine system plays a vital role in mediating the reinforcing effects of nicotine.  
nAChRs have been shown to be highly localized in the VTA, a major point of 
origin of mesolimbic DA projections.  Therefore, the first aim of this dissertation 
was to investigate whether nicotine would be self-administered directly into the 
VTA of Wistar rats.  The intracranial self-administration (ICSA) technique has 
been used to identify specific brain regions involved in mediating the reinforcing 
effects of drugs of abuse (Bozarth and Wise 1980; Goeders and Smith 1987).  
This procedure has been used to demonstrate site-specific self-administration of 
several drugs including EtOH, morphine, and amphetamine (Gatto et al. 1994; 
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Bozarth and Wise 1981; Chevrette et al. 2002).  Functional heterogeneity 
between the anterior and posterior portions of the VTA has also been reported 
(Ikemoto et al. 1998), and drugs such as EtOH have been shown to be self-
administered into the pVTA but not into the aVTA (Rodd-Henricks et al. 2000a).  
Therefore, it was hypothesized that nicotine would be self-administered directly 
into the pVTA of Wistar rats in a dose-dependent manner. 
 Given that adolescence is a time period when the brain is especially 
susceptible to the effects of drugs of abuse, it is no surprise that the vast majority 
of smokers begin using tobacco during their teenage years.  For the next three 
aims of this dissertation, the long-lasting effects of nicotine exposure during 
adolescence were examined.  Because nicotine exerts its reinforcing properties 
by stimulating the mesolimbic DA system and causing DA release in the NAc, the 
second aim of this dissertation was to investigate whether exposure to nicotine 
during adolescence would result in changes in nicotine-induced DA release in the 
NAc during adulthood in Wistar rats.  Using the information gathered in the first 
aim of this dissertation about the reward-mediating actions of nicotine within the 
VTA, it was hypothesized that DA release in the NAcc as a result of nicotine 
injections directly into the VTA would be enhanced in rats that had been exposed 
to nicotine during adolescence. 
 Following investigation of nicotine-mediated DA release in the NAc, the 
next logical step was to study the effects of adolescent nicotine treatment on a 
behavioral correlate of mesolimbic dopaminergic activation.  Previous research 
has established that the locomotor stimulating effect of nicotine is mediated by 
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mesolimbic DA activity (Clarke et al. 1988).  Therefore, the third aim of this 
dissertation was to investigate the effects of adolescent nicotine exposure on 
behavioral sensitivity to nicotine during adulthood in Wistar rats.  A locomotor 
activity study was employed to investigate the initial sensitivity of adolescent-
exposed rats to nicotine as well as the development of behavioral sensitization 
following repeated daily injections of the drug.  In the locomotor sensitization 
paradigm, repeated doses of a drug incrementally increase behavioral 
responsiveness to the drug, and this effect persists over time (Robinson and 
Berridge 1993).  It was hypothesized that nicotine exposure during adolescence 
would yield an increase in sensitivity to the locomotor-activating effects of 
nicotine during adulthood. 
 Finally, the high rate of co-abuse of nicotine and EtOH in human 
populations prompts the question of whether exposure to one drug can cross-
sensitize a system to the effects of the other.  Since persistent neurobiological 
and behavioral effects of adolescent nicotine exposure had been explored in the 
second and third aims of this dissertation, the fourth aim was to investigate the 
effects of adolescent nicotine exposure on EtOH consumption during adulthood.  
Adolescent nicotine exposure results in a number of long-lasting behavioral 
effects, and several previous studies have shown that EtOH consumption was 
increased when preceded by nicotine treatment (Pothoff et al. 1983; Blomqvist et 
al. 1996).  Therefore, it was hypothesized that adolescent nicotine exposure 
would result in increased EtOH consumption during adulthood.  This experiment 
was conducted not only in Wistar rats but also in alcohol-preferring P rats, since 
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earlier studies have shown that P rats may be more sensitive to certain effects of 
nicotine (Gordon et al. 1993; Le et al. 2006).  It was also hypothesized that the 
effects of adolescent nicotine exposure on adulthood EtOH consumption would 
be enhanced in P rats as compared to Wistar rats, because there may be an 
underlying genetic influence on the co-abuse of these two drugs.   
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II.  MATERIALS AND METHODS 
 
A.  Aim 1: Nicotine intracranial self-administration 
 
1.  Animals 
 Female Wistar rats (Harlan, Indianapolis, IN) arrived in the laboratory at 
approximately post-natal day (PD) 60 and were pair-housed until after cannula 
implantation surgery 2-4 weeks later.  Female rats were used because they have 
been used in our previous ICSA studies, and because females maintain their 
body weight and head size better than male rats, which allows for more accurate 
stereotaxic placements (Ikemoto et al. 1998).  Estrous cycles were not monitored 
in the current study, although previous studies have indicated that ICSA behavior 
is not affected by estrous cycle (Gatto et al. 1994; Rodd-Henricks et al. 2000a).  
The vivarium conditions were constant for this and all subsequent experiments in 
this dissertation.  It was maintained on a 12-hour reverse light/dark cycle (lights 
off at 0900 hours) with food and water available ad libitum, and temperature 
(21°C) and humidity (50%) were controlled. 
 At the time of surgery, animals weighed approx. 250-300 g.  With the 
subjects under isoflurane anesthesia, a 22 gauge guide cannula were 
stereotaxically implanted into the right hemisphere; the guide cannulae was 
aimed 1.0 mm above the target region.  Coordinates (Paxinos and Watson 1998) 
for placements into the pVTA were 5.7 mm posterior to bregma, 2.1 mm lateral to 
the midline, and 8.5 mm ventral from the surface of the skull at a 10 degree angle 
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to the vertical.  In between experimental sessions, a 28 gauge stylet was placed 
into the guide cannula and extended 0.5 mm beyond the tip of the guide.  After 
surgery, rats were housed individually and allowed to recover for 7 days.  
Animals were handled for at least 5 min daily after the third recovery day.  
Animals were not acclimated to the experimental chambers before the 
commencement of data collection. 
 
2.  Drugs and solutions 
 Appropriate amounts of nicotine ((−)-1-Methyl-2-(3-pyridyl)pyrrolidine (+)-
bitartrate salt, Sigma-Aldrich) were dissolved into artificial cerebrospinal fluid 
(aCSF), which consisted of 120.0 mM NaCl, 4.8 mM KCl, 1.2 mM KH2PO4, 1.2 
mM MgSO4, 25.0 mM NaHCO3, 2.5 mM CaCl2, and 10.0 mM D-glucose (pH of 
7.3 + 0.1).  Doses used in this study were 10, 50, 100, 200, 400, and 800 µM 
nicotine.  Blood and brain nicotine concentrations in human smokers are roughly 
100-500 nM (Karan et al. 2003), but previous animal studies involving intra-VTA 
microinjections of nicotine have used doses in the mM range, from 0.4 to 25 mM 
(David et al. 2006; Ikemoto et al. 2006), so the range of doses used here were 
chosen because they fell in between these two extremes.   
 
3.  Apparatus 
 The test chambers (30 x 30 x 26 cm) were situated in sound-attenuating 
cubicles (64 x 60 x 50 cm; Colbourn Instruments, Allentown, PA) and illuminated 
by a dim house light during testing.  Two identical levers (3.5 x 1.8 cm) were 
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mounted on a single wall of the test chamber, 15 cm above a grid floor, and were 
separated by 12 cm.  Directly above each lever was a row of three different 
colored cue lights.  The light (red) to the far right over the active bar was 
illuminated during resting conditions.  An electrolytic microinfusion transducer 
(EMIT) system (Bozarth and Wise, 1980) was used to control microinfusions of 
drug or vehicle.  Two platinum electrodes were placed in an infusate-filled gas-
tight cylinder (20 mm in length by 6 mm in diameter) equipped with a 28 gauge 
injection cannula (Plastics One, Roanoke VA).  The electrodes were connected 
by a spring-coated cable (Plastics One) and a swivel to a constant current 
generator (MNC, Shreveport LA) that delivered 6 µA of quiescent current and 
200 µA of infusion current between the electrodes.  Depression of the active 
lever delivered the infusion current for 5 sec, which lead to the rapid generation 
of H2 gas (raising the pressure inside the gas-tight cylinder), and, in turn, forced 
100 nl of the infusate through the injection cannula.  During the 5-sec infusion 
and additional 5-sec timeout period, the house light and red cue light turned off, 
and the green cue light over the active lever flashed on and off at 0.5 sec 
intervals.    
 
4.  General test condition 
 Subjects were brought into the testing room, the stylet removed, and the 
injection cannula was screwed into place.  Injection cannulae extended 1.0 mm 
beyond the tip of the guide.  The test chambers were equipped with two levers.  
Depression of the “active lever” (FR1 schedule of reinforcement) caused the 
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delivery of a 100 nl bolus of infusate over 5 sec, followed by a 5-sec timeout 
period.  During that 10-sec total time, additional responses on the active lever 
were recorded but did not result in additional infusions.  Responses on the 
“inactive lever” were recorded but did not result in infusions.  The assignment of 
active and inactive levers with respect to right and left was counterbalanced 
among subjects, with the active and inactive levers remaining the same for each 
rat throughout the experiment.     
 
5.  Dose response study 
 Wistar rats were randomly assigned to one of five groups (n = 6-10 per 
group).  Each rat was tested during seven sessions in the self-administration 
chamber for 4 hours each session, with sessions occurring every other day.  One 
group received infusions of vehicle (aCSF) for all seven sessions.  The other 
groups received infusions of either 10, 50, 100, 200, 400, or 800 µM nicotine for 
the first four sessions.  During the 5th and 6th sessions, all groups received 
infusions of aCSF.  During the 7th session, rats were allowed to respond for their 
original infusate.  This seven-session paradigm is the standard for ICSA 
experiments in our laboratory, as a previous study on self-administration of 
ethanol indicated that stable lever responding was attained by sessions 3 and 4, 
extinction was reached within two sessions, and active lever responding was 
reinstated within one session when original infusate was restored (Rodd-
Henricks et al. 2000a).  A desktop computer equipped with an operant control 
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system recorded the data and controlled delivery of the infusate in relation to 
lever responding. 
 At the end of the experimental day, rats were euthanized in a CO2 
chamber, and 1% bromophenol blue (0.5 µl) was injected into the infusion site.  
The animals were decapitated and brains removed, and immediately frozen at  
-70°C.  Frozen brains were sliced in a cryostat microtome into 40 µM sections.  
Sections were stained with cresyl violet and examined under a light microscope 
for verification of the injection site using the rat brain atlas of Paxinos and 
Watson (1998). 
  
6.  Statistical analysis 
 Data analysis consisted of a one-way analysis of variance (ANOVA) 
performed on the number of infusions across the four acquisition sessions.  
Additionally, for each individual group, lever discrimination was determined by a 
Lever (active or inactive) x Session mixed ANOVA with a repeated measure of 
Session.  Lever discrimination is a key factor when a stimulant is self-
administered (e.g., nicotine, cocaine, amphetamine) to distinguish between 
reinforcement-contingent behavior and drug-stimulated locomotor activity.  To 
study extinction (5th and 6th sessions) and reinstatement (7th session) in each 
infusate group, first a one-way ANOVA was performed on the active lever 
presses in sessions 4-7.  Then, paired t-tests (two-tailed) with a 95% confidence 
interval were used to determine whether the lever responding on aCSF days was 
significantly different than on days when nicotine was available. 
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B.  Aim 2: Effects of adolescent nicotine exposure on adulthood nicotine-
stimulated DA release in the NAc 
 
1.  Animals 
 Male Wistar rats (Harlan, Indianapolis, IN) arrived in the laboratory at PD 
23-25 and were housed 4 to a cage, then later adjusted to pair-housed when 
body weights reached approximately 300 g.  Following cannulae implantation 
surgery at approx PD 75-80, they were single housed. 
 With the subjects under isoflurane anesthesia, two guide cannulae were 
implanted at a 10 degree angle to the vertical.  For the microinjection site (pVTA), 
a 22-gauge cannula was used, and for the microdialysis probe site (NAc), an 18-
gauge cannula was used.  Coordinates (Paxinos and Watson 1998) for 
placements into the posterior VTA were 5.7 mm posterior to bregma, 2.1 mm 
lateral to the midline, and 8.5 mm ventral from the surface of the skull.  Cannulae 
were placed at a 10 degree angle to the vertical.  Coordinates for the NAc shell 
were 1.7 mm anterior to bregma, 2.3 mm lateral to the midline, and 5.4 mm 
ventral from the surface of the skull.  In between experimental sessions, stylets 
were placed into the guide cannulae which extended 0.5 mm beyond the tip of 
the guides.  After surgery, rats were housed individually and allowed to recover 
for at least 5 days before the insertion of microdialysis probes.  Rats were 
habituated to the Plexiglas microdialysis chambers (22.5 x 44.5 x 38 cm, width x 
length x height) for approximately 4-5 hours daily, and handled for at least 10 
minutes on the 3 days immediately preceding the microdialysis experiment. 
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 On the third habituation day, after removal from the chambers, animals 
were briefly anesthetized, and loop-style microdialysis probes were inserted into 
the guide cannulae aimed at the NAc and cemented in place.  Probes were made 
as previously described (Perry and Fuller 1992; Kohl et al. 1998) and inserted 
into the guides so that the loop was oriented along the anterior/posterior axis.  
The probes extended past the tip of the guide cannulae a total of 3.0 mm: 2.0 
mm of this was active microdialysis membrane. 
 
2.  Drugs and solutions 
 For adolescent exposure, 0.5 mg/kg nicotine ((−)-1-Methyl-2-(3-
pyridyl)pyrrolidine (+)-bitartrate salt, Sigma-Aldrich) or saline was administered 
via a once-daily subcutaneous (s.c.) injection on PD 30-41.  Animals were 
weighed, injected, and placed directly back in the home cage.  Nicotine dose was 
based on several previous studies (including Adriani et al. 2006; Belluzzi et al. 
2004; Berg and Chambers 2008).  The dose was calculated as the weight of the 
base, and was dissolved in a sterile 0.9% saline solution (pH adjusted to 7.1 + 
0.1) and delivered at an injection volume of 1 ml/kg.   
 For the intra-VTA microinjections, nicotine solutions were prepared as 
described above for the ICSA experiments in section II.A.2.  The doses used in 
this experiment were 100 and 200 µM, because they were determined to be the 
optimal doses in the ICSA dose-response experiment in the first part of this 
dissertation.   
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 For microdialysis in the NAc, a standard aCSF that did not include D-
glucose was used.  Microdialysis aCSF consisted of 145.0 mM NaCl, 2.7 mM 
KCl, 1.0 mM MgCl2, 2.5 mM CaCl2, and 2.0 mM Na2HPO4 (pH of 7.4 + 0.05). 
 
3. Microinjection−microdialysis test procedure 
On the experimental day, animals were transferred to Plexiglas testing 
chambers.  The inputs of the probes were connected to a microinfusion syringe 
pump (Harvard Apparatus, South Natick, MA) through a length of clear 
polyethylene (PE) tubing.  The outlets were connected to opaque black PE tubing 
to reduce light-induced degradation of DA, and the samples were collected into 
0.5-ml PE tubes containing 5.0 µl of 0.1 N perchloric acid. 
 Microdialysis aCSF was perfused through the probes at a flow rate of 1.0 
µl/min for 2 hr for washout.  After the 2-hr equilibration, samples were collected 
every 20 min.  The first 3 samples collected were considered baseline samples. 
 After collection of the baseline samples, the injection cannula was inserted 
into the VTA guide cannula.  The EMIT system was used for injections in this 
experiment, as described in section II.A.3. above.  This time, injection delivery 
was controlled by the experimenter rather than a two-lever operant system.  
Immediately after insertion of the injection cannula, injections of either aCSF, 
100, or 200 µM nicotine were delivered for a duration of 5 sec each, 3 times per 
min, for 10 min.  This was done to mimic a temporal pattern of microinjections 
that a rat might self-administer in the ICSA paradigm (Rodd-Henricks et al. 
2000a).  The injector cannula was gently removed approximately 1 min following 
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the last microinjection.  Samples continued to be collected every 20 min until a 
total of 7 samples had been collected after the microinjections. 
 All samples were immediately frozen on dry ice and stored at −70°C until 
assayed.  At the end of the experimental day, rats were euthanized in a CO2 
chamber, and 1% bromophenol blue (0.5 µl) was injected into the infusion site 
and perfused through the microdialysis probe.  The animals were decapitated 
and brains removed, and immediately frozen at −70 degrees C.  Frozen brains 
were sliced in a cryostat microtome into 40 µM sections.  Sections were stained 
with cresyl violet and examined under a light microscope for verification of the 
injection and probe sites using the rat brain atlas of Paxinos and Watson (1998). 
 
4.  High-Performance Liquid Chromatography 
 The microdialysis samples were analyzed for DA content with a reverse-
phase high-performance liquid chromatography coupled with an electrochemical 
detection (HPLC-EC) system.  Samples were loaded into a 5-µl loop and injected 
onto a small-bore analytical column (BDS Hypersil C18, 150 mm × 2.1 mm, 
Thermo). The mobile phase (50 mM phosphoric acid, 100 mg/l OSA, 0.1 mM 
EDTA, 8 mM KCl, and 6.0% acetonitrile, pH 6.0) was delivered by a Shimadzu 
LC-20AD solvent delivery system (Shimadzu Corporation, Tokyo Japan).  DA 
was detected by a VT-03 glassy carbon electrode (Antec Leyden, The 
Netherlands) and an Antec DECADE II amperometric detector (Antec Leyden, 
The Netherlands) with the potential set at 320 mV and sensitivity setting of 50 
pA/V. The outputs from the detector were sent to a ChromPerfect (Version 5.5.5, 
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Justice Innovations, Inc., Palo Alto, CA) chromatography data analysis system.  
The lower detection limit for dopamine was approximately 0.1 nM.  Calibration 
was performed using standards of known DA concentration. 
 
5.  Statistical analysis 
 DA levels in the NAc were normalized and expressed as percent of 
baseline.  Timecourse data for DA release in the NAc in response to pVTA 
microinjections were analyzed using a two-way ANOVA (Adolescent Treatment x 
Time) with a repeated measure of Time.  Where appropriate, individual means 
were compared using paired t-tests with a 95% confidence interval. 
 
  
C.  Aim 3: Effects of adolescent nicotine exposure on adulthood behavioral 
sensitivity to nicotine 
 
1.  Animals 
 Male Wistar rats (Harlan, Indianapolis, IN) arrived in the laboratory at PD 
23-25 and were housed 4 to a cage, then later adjusted to pair-housed when 
body weights reached approximately 300 g.   
 
2.  Drugs and solutions 
 Drugs, solutions, and adolescent nicotine exposure regimen were as 
described above in section II.B.2.  For this experiment, there were two different 
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adolescent nicotine exposure groups.  One group received s.c. injections of 0.25 
mg/kg nicotine, another received 0.5 mg/kg nicotine, and a control group 
received an equivalent volume of saline. 
 
3.  Apparatus 
 LMA sessions took place in Plexiglas recording chambers (43.2 x 43.2 x 
30.5 cm), which were each equipped with 16 infrared beam transmitters 
spanning the x and y axes of the field (Med Associates, Inc., St. Albans, VT).  
Transmitter and detector arrays for translational motion were located 5 cm from 
the chamber floor and spaced 2.5 cm apart.  Data were collected using the 
Activity Monitor 5.0 software (Med Associates, Inc., St. Albans, VT), which was 
configured to separate small, quick movements (stereotypic counts) from 
translational locomotion (ambulatory beam break counts, distance traveled).   
 
4.  General test condition 
 Starting on PD 80, locomotor behavior was assessed over ten 2-hour 
sessions (1 session per day) occurring Monday through Friday of two 
consecutive weeks.  Each 2-hour locomotor recording session consisted of a 1-
hour baseline phase and a 1-hour post-injection phase.  Activity data were 
collected in 10-min blocks.  After each 1-hour baseline period ended, animals 
received a subcutaneous injection of saline or 0.25 mg/kg or 0.5 mg/kg nicotine, 
according to randomly assigned drug treatment groups.  Each animal received 
the same dose of nicotine (or saline) across all ten days of the LMA study. 
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5.  Statistical analysis 
 Analysis for the LMA data consisted of a repeated measures ANOVA with 
between-subject variables of adolescent nicotine group or adult nicotine group 
and repeated measures of session.  Roy’s Largest Root was used to correct the 
violations of the assumptions of the repeated measures ANOVA test, namely 
sphericity and heterogeneity of variance.  Additionally, LMA was decomposed 
into 10-min blocks and analyzed through a repeated-measures ANOVA with 
between-subject variables of adolescent nicotine group or adult nicotine group 
and repeated measures of block.  Post hoc analyses (Student-Newman-Keuls 
and Tukey’s b) were used to determine which groups were significantly (p < 0.05) 
different from each other. 
 
D.  Aim 4: Effects of adolescent nicotine exposure on adulthood EtOH drinking 
behavior 
 
1.  Animals 
 Male Wistar (Harlan, Indianapolis, IN) or alcohol-preferring P (Indiana 
University, Indianapolis, IN) arrived in the laboratory at PD 23-25 and were 
housed 4 to a cage, then later adjusted to pair-housed when body weights 
reached approximately 300 g.  A control group of Wistar rats, which received 
nicotine exposure first during adulthood rather than adolescence, arrived at 
approximately PD 60 and were pair-housed. 
 
 34 
2.  Drugs and solutions 
 Drugs, solutions, and adolescent nicotine exposure regimen were as 
described above in section II.B.2.  For the adult control group of Wistar rats, 
nicotine injections were given on PD 60-71. 
 For EtOH drinking, 95% (190 proof) EtOH was mixed with deionized water 
to the appropriate volume/volume concentrations (5, 10, 15, or 30%).  During 
drinking studies, EtOH solutions were stored in 8-liter plastic carboys (Nalgene 
Labware) in the vivarium for convenience, and fresh solutions were made every 2 
weeks. 
 
3.  Experimental procedure 
 At PD 70 days of age (or PD 110, for the Wistar age control group), the 
animals were transferred to hanging wire mesh cages (1 rat per cage) with water 
and food freely available throughout the experiment.  Following 5 days of 
habituation to the hanging wire mesh cages, all rats were given 24-hour 
concurrent access to multiple concentrations of ethanol (EtOH).  Multiple 
concentrations were used so that any shift in preference between lower and 
higher concentrations of EtOH could be observed.  For Wistar rats, EtOH was 
available at concentrations of 5% and 10% v/v.  Initially, those same EtOH 
concentrations were used for the P rats, to allow for direct comparisons to be 
drawn between the Wistar and P rats.  In addition, a separate cohort of P rats 
underwent the same adolescent nicotine exposure treatment as the other 
cohorts, and was given access to higher concentrations of EtOH (15% and 30%, 
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v/v) during adulthood.  This was done to counteract the possibility of a ceiling 
effect in the cohort of P rats drinking the lower EtOH concentrations, as it has 
been shown that P rats will voluntarily drink EtOH at concentrations of up to 30%. 
 Access to EtOH solutions was continuous for the first 8 weeks of the 
experiment.  The first 4 weeks are considered the acquisition phase of EtOH 
drinking behavior, and the second 4 weeks are considered the maintenance 
phase.  Following those 8 weeks, rats underwent three cycles of 2 weeks of 
EtOH deprivation and 2 weeks of EtOH reinstatement.  This was done to look for 
possible adolescent-nicotine-induced changes in the expression of an Alcohol 
Deprivation Effect (ADE), defined as a temporary increase in EtOH intake 
compared to baseline drinking conditions, following a period of EtOH deprivation. 
 Rats had continuous access to their drinking solutions except during 
measurement of body and bottle weights.  Beginning on the first EtOH access 
day, body and bottle weights were obtained, at least 6 days per week, using a 
Sartorius Balance BP 1600 and Sartorius Interface V24/V28-RS232C(-S)/423 
(Sartorius Instruments, McGaw Park, IL) and recorded by a personal computer 
program (Software-Wedge, Professional Edition v 5.0 for DOS; Sartorius 
Instruments).  Weights were rounded to the nearest 0.1 g.  Weights for the 7th 
day of the week, when not recorded, were determined to be the average of the 
weights obtained on the preceding and following days. 
 Bottles for water and EtOH were standard glass bottles with a capacity of 
approximately 300 ml of fluid, with a stopper (no. 10) holding an angled (~135°) 
stainless steel sipper tube with ball-bearing tip.  Spillage was calculated by using 
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a set of “spill bottles,” hanging on an empty cage, which were removed and 
weighed along with the other bottles.  The fluids in the spill bottles were the same 
as the fluids rats had access to, i.e. water and two concentrations of EtOH.  An 
average of approximately 0.5 ml of fluid was spilled with each weighing, so this 
amount was subtracted from all daily bottle weights.  All bottles were refilled at 
least twice per week, and were replaced every 2 weeks. 
 
4.  Statistical analysis 
 Analysis for the EtOH intake data and preference data consisted of a 
repeated measures ANOVA with a between-subject variable of Adolescent 
Treatment and repeated measures of Week (or Day, in the case of analysis of 
initial 7 days of EtOH drinking).  Roy’s Largest Root was used to correct the 
violations of the assumptions of the repeated measures ANOVA test, namely 
sphericity and heterogeneity of variance.  For the EtOH intake during each 
relapse EtOH drinking session following periods of deprivation, repeated 
measures ANOVAs with a between-subject variable of Adolescent Treatment 
and repeated measures of Day were used.  Then, paired t-tests (two-tailed) with 
a 95% confidence interval were used to compare EtOH intake on individual re-
exposure days to the pre-deprivation baseline EtOH intake amount. 
 37 
III.  RESULTS 
 
A.  Nicotine intracranial self-administration 
 
 The posterior VTA (pVTA) was defined neuroanatomically as the VTA 
region at the level of the interpeduncular nucleus, coronal sections from -5.6 to  
-6.3 mm bregma (Fig. 1)  Cannula placements outside the pVTA included 
injection sites located in the substantia nigra (both in the pars compacta, SNc;  
and pars reticulata, SNr), and red nucleus (RN).   
 In our seven-session intracranial self-administration (ICSA) paradigm, the 
first four sessions were considered “acquisition” of the lever-pressing behavior.  
The 5th and 6th sessions, during which responses on the active lever resulted in 
infusions of aCSF rather than nicotine, were considered the “extinction” sessions.  
The 7th session, during which the original nicotine infusate was returned, was 
considered the “reinstatement” session.  A range of nicotine concentrations 
infused into the pVTA supported response-contingent behaviors (Fig. 2).  Since 
rats typically establish stable responding by the third 4-hour ICSA session, a one-
way ANOVA was used to compare the average number of nicotine infusions 
received during sessions 3 and 4, and it revealed a significant main effect of 
Group (F6,47 = 4.459, p < .0001).  Post hoc comparisons (Tukey’s b) indicated 
that the 50, 100, and 800 µM groups received significantly more infusions than 





Figure 1.  Representative placements of the microinjector cannulae within the 
pVTA.  Distances (in millimeters) from bregma are shown to the right of the 
diagrams.  This figure was adapted from Paxinos and Watson (1998). 
-5.6 mm 
-5.8 mm 





Figure 2.  The mean (+ SEM) number of infusions during intracranial self-
administration sessions 3 and 4 by Wistar rats self-infusing 10-800 µM of 
nicotine, or aCSF (n = 6-10 per group).  * Indicates that the average number of 
infusions is significantly higher than the aCSF group (p < 0.05).  ** Indicates that 
the average number of infusions is significantly greater than both the aCSF and 
10 µM groups (p < 0.05). 
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received significantly more infusions than both the aCSF and 10 µM groups (Fig. 
2).   
 To determine whether the Wistar rats showed discrimination between the 
active and inactive levers, first a 3-way ANOVA was performed with repeated 
measures of Lever (active or inactive) and Session and a between-subjects 
factor of Group using all nicotine dose groups.  The ANOVA indicated a 
significant Session x Lever x Group interaction (F36,282 = 1.563, p = 0.026).  Next, 
each nicotine dose Group was held constant and 2-way ANOVAs were 
performed with repeated measures of Lever and Session across all 7 sessions.  
Active and inactive lever presses for each infusate group are represented in Fig. 
3 and described below.   
 To assess whether extinction (in sessions 5 and 6) and reinstatement (in 
session 7) of response-contingent behavior took place, each Group was held 
constant and repeated measures ANOVAs were performed with a repeated 
measure of Session, using sessions 4 thru 6 for extinction, and sessions 5 thru 7 
for reinstatement.  Finally, paired t-tests were performed to compare active lever 
responding between sessions. 
 For the Wistar rats self-infusing aCSF during all 7 sessions, there was no 
significant main effect of Lever (F1,8 = 0.016, p = 0.902) or Session x Lever 
interaction (F6,3 = 1.877, p = 0.323) during sessions 4-6 or 5-7.  The average 
number of responses in all sessions was generally low on both levers (< 25 
responses per session).   
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Figure 3.  The mean (+ SEM) number of active (closed circles) and inactive 
(open squares) lever presses for Wistar rats self-administering aCSF (inset) or 
10-800 µM nicotine into the pVTA during sessions 1-4 and session 7 (n = 6-10 
per group).  Nicotine was replaced by aCSF for sessions 5 and 6.  * Indicates 
significantly (p < 0.05; Tukey’s b) higher active lever responding compared to 
active lever responding by rats self-administering aCSF.  + Indicates lever 




 For the 10 µM nicotine group, the 2-way ANOVA indicated a significant 
main effect of Lever (F1,5 = 13.479, p = 0.014), but no Session x Lever interaction 
(F3,3 = 1.042, p = 0.487).  Paired t-tests indicated that these rats responded 
significantly more on the active than inactive lever during the first three 
acquisition sessions (df = 5, p values < 0.045).  When aCSF was substituted for 
nicotine during sessions 5 and 6, a repeated measures ANOVA on sessions 4 
thru 6 revealed a significant main effect of Session (F2,4 = 7.042, p = 0.049) 
which indicated extinction of the response-contingent behavior, and lever 
discrimination was no longer apparent (p values > 0.073).  When 10 µM nicotine 
was returned in session 7, an ANOVA on sessions 5 thru 7 showed a significant 
main effect of Session (F2,4 = 7.152, p = 0.048), which indicated reinstatement of 
active lever pressing, and rats responded significantly more on the active than 
the inactive lever (p = 0.043).  However, across all sessions, the average number 
of active lever responses was relatively low (< 25 responses per session) and did 
not differ from active lever responding by the aCSF group. 
 A 2-way ANOVA on the lever presses in the 50 µM nicotine group 
revealed a significant main effect of Lever (F1,6 = 17.473, p = 0.006) but no 
Session x Lever interaction (F6,1 = 6.787, p = 0.286).  Paired t-tests indicated that 
this group of rats demonstrated significantly greater responding on the active 
lever than the inactive lever during all 4 acquisition sessions (df = 6, p values < 
0.022).  When aCSF replaced nicotine for the two extinction sessions, lever 
discrimination was apparent during the 5th session (p = 0.037) but no longer 
present in the 6th session (p = 0.245).  When 50 µM nicotine was returned in the 
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reinstatement session, active lever responding was once again significantly 
greater than inactive lever responding (p = 0.012).  A repeated measures 
ANOVA on the number of active lever presses during sessions 4 thru 6 indicated 
no significant main effect of Session (F2,5 = 3.791, p = 0.10), and a similar 
ANOVA on the active lever presses during sessions 5 thru 7 also approached 
significance (F2,5 = 2.069, p = 0.06). 
 For the 100 µM nicotine group, a 2-way ANOVA indicated a significant 
main effect of Lever (F1,9 = 17.094, p = 0.003) but no Session x Lever interaction 
(F6,4 = 2.572, p = 0.190).  Paired t-tests showed lever discrimination during all but 
the 1st session (df = 9, p values < 0.024), including the sessions in which aCSF 
replaced the nicotine infusate (sessions 5 and 6).  A repeated measures ANOVA 
on the active lever presses in sessions 4-6 revealed a significant main effect of 
Session (F2,8 = 6.023, p = 0.025), and paired t-tests indicated that active lever 
presses in sessions 5 and 6 were significantly lower than in session 4 (p values < 
0.014), indicating extinction of the response-contingent behavior.  When 
comparing sessions 5-7, a repeated measures ANOVA indicated no significant 
main effect of Session (F2,8 = 3.202, p = 0.095). 
 For the 200 µM nicotine group, a 2-way ANOVA revealed a significant 
main effect of Lever (F1,9 = 134.3, p < 0.001) but no Session x Lever interaction 
(F6,4 = 2.584, p = 0.189).  Paired t-tests indicated discrimination between the 
active and inactive levers during all 7 sessions of the experiment (df = 9, p values 
< 0.026).  To assess extinction, a repeated measures ANOVA performed on the 
number of active lever presses during sessions 4-6 revealed a significant main 
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effect of Session (F2,8 = 6.001, p = 0.026), and paired t-tests indicated that active 
lever responses were significantly lower in sessions 5 and 6 than session 4 (p 
values < 0.021).  An ANOVA on sessions 5-7 showed no main effect of Session 
(F2,8 = 1.854, p = 0.218).  
 A 2-way ANOVA on the rats self-infusing 400 µM nicotine revealed a 
significant main effect of Lever (F1,5 = 15.810, p = 0.011) but no Session x Lever 
interaction (F3,3 = 2.288, p = 0.257).  Paired t-tests indicated significant lever 
discrimination during sessions 4, 5, and 7 (df = 5, p values < 0.02), but not 
session 6.  Repeated measures ANOVAs performed on sessions 4-6 and 
sessions 5-7 revealed no significant main effect of Session (F2,4 < 2.661, p 
values > 0.184). 
 Finally, for the 800 µM nicotine group, a 2-way ANOVA indicated a 
significant main effect of Lever (F1,5 = 11.546, p = 0.019) but no Session x Lever 
interaction (F3,3 = 0.297, p = 0.828).  Paired t-tests indicated that lever 
discrimination was observed only during the sessions 1 and 6 (df = 5, p values < 
0.046).  Repeated measures ANOVAs revealed that neither extinction (sessions 
4-6) nor reinstatement (sessions 5-7) of active lever pressing were significant 
(F2,4 < 3.717, p values > 0.122).   
 A one-way ANOVA was performed on the average number of active lever 
presses during all 7 sessions in all groups, and this indicated that, in at least 
three of the five nicotine sessions, rats in the 50-800 µM nicotine groups 
responded significantly (p values < 0.05; Tukey’s b) more on the active lever for 
nicotine infusions than did the rats responding for aCSF (Fig. 3).   
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 Wistar rats self-infusing the same concentrations of nicotine into areas 
surrounding the pVTA, including the SNc, SNr, and RN, showed an overall low 
level of infusions and active lever responding throughout all sessions.  These rats 
displayed comparable levels of infusions and active lever responding with the 
rats self-infusing aCSF into the pVTA.  The average number of infusions by each 
injector placement group in sessions 3 and 4 are depicted in Fig. 4.  A one-way 
ANOVA indicated no significant differences among the three non-pVTA groups 
(F2,41 = 2.248, p = 0.118).   
 The number of active lever presses by the rats self-infusing nicotine into 
areas outside the pVTA were generally low compared to the pVTA groups: 
approximately 20-30 lever presses/session for rats self-infusing nicotine into the 
subregions of the SN, and generally 10 or fewer lever presses/session for the 
rats self-infusing into the RN.  However, some lever discrimination within injector 
placement groups was observed (Fig. 5).  A 3-way ANOVA performed with 
repeated measures of Lever (active or inactive) and Session and a between-
subjects factor of Injector Placement revealed a significant main effect of Lever 
(F1,41 = 8.879, p = 0.005).  Next, Injector Placement was held constant and 
ANOVAs were performed with repeated measures of Lever and Session.  For the 
rats infusing concentrations of nicotine into the SNr, a significant main effect of 
Lever was observed (F1,13 = 10.275, p = 0.007), but there was no Session x 
Lever interaction (F6,8 = 0.892, p = 0.543).  Paired t-tests indicated that these rats 
responded significantly more on the active lever than the inactive lever in all but 





Figure 4.  The mean (+ SEM) number of infusions during intracranial self-
administration sessions 3 and 4 by rats self-administering various concentrations 
of nicotine (10 – 800 µM) into the SNr (n = 14), SNc (n = 20), or RN (n = 10), as 
well as for rats self-administering aCSF into the pVTA (right of dotted line).  No 
significant differences between injector placement groups were observed.  
Number of rats in each group self-infusing each nicotine concentration is 
indicated in the inset. 
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Figure 5.  The Mean (+ SEM) number of active (closed circles) and inactive 
(open circles) lever presses for rats self-administering various concentrations of 
nicotine (10 – 800 µM) into the SNr (top panel, n = 14), SNc (middle panel, n = 
20), or RN (bottom panel, n = 10) during sessions 1-4, aCSF in sessions 5 and 6, 
and the original nicotine infusate in session 7.  * Indicates significant (p < 0.05) 
lever discrimination within a given injector placement group. 
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concentrations of nicotine into the SNc, a significant main effect of Lever was 
observed (F1,19 = 5.005, p = 0.037), but there was no Session x Lever interaction 
(F6,14 = 0.798, p = 0.587).  Paired t-tests indicated significant lever discrimination 
during sessions 5-7 (df = 19, p values < 0.006; Fig. 5, middle panel).  For the rats 
infusing nicotine into the RN, a repeated measures ANOVA indicated neither a 
significant main effect of Lever (F1,9 = 0.094, p = 0.767) nor a Session x Lever 
interaction (F6,4 = 2.511, p = 0.196).  No lever discrimination was observed in this 
group (Fig. 5, bottom panel). 
 
 
B.  Effects of adolescent nicotine exposure on adulthood nicotine-stimulated DA 
release in NAc 
 
 Only data from animals with the microinjector cannula correctly implanted 
in the pVTA and the microdialysis probe correctly implanted in the shell of the 
NAc were included in the analysis.  Representative anatomical placements of the 
NAc probes and the pVTA injector cannulae are depicted in Fig. 6A and 6B, 
respectively.  The pVTA was defined neuroanatomically as the VTA region 
located at -5.6 to -6.3 mm relative to bregma.  Because of the diameter and 
length of the probes, a portion of the active probe membrane was often located 
within the NAc core.  Therefore, only data from rats with the probes placed at 




Figure 6.  Representative placements of (A) the microdialysis probes within the 
NAc and (B) the microinjector cannulae within the pVTA.  Distances (in 
millimeters) from bregma are shown to the right of the diagrams.  This figure was 
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Numerous unanticipated challenges were faced with the HPLC machine 
during the data analysis portion of this study.  Some of the HPLC chromatograms 
obtained during this study showed puzzling inconsistencies in DA peak size and 
peak time, even within individual animals.  Inconsistent amounts of storage time 
for the microdialysis samples between collection and HPLC analysis may have 
contributed to this issue, but other unknown factors were likely also at play.  After 
consulting with HPLC specialists in the laboratory, data from some animals had 
to be excluded based on these inconsistencies.  This resulted in a low n for some 
groups, particularly the groups that received nicotine microinjections of 100 µM 
during microdialysis.  Time constraints prevented the experiment, with its roughly 
2.5-month time course, from being repeated in additional animals.   
Examination of basal extracellular DA levels (average of the three 20-
minute baseline samples) in the NAc using an unpaired t-test revealed no 
differences between adolescent treatment groups (t21 = 0.594, p = 0.117).  
Average baseline DA levels were approximately 4.8 + 1. 
Microinjection of 100 or 200 µM nicotine into the pVTA increased 
extracellular DA in the NAc to approximately 160% of baseline in Wistar rats 
treated with saline during adolescence (Fig. 7).  However, in rats treated with 0.5 
mg/kg nicotine during adolescence, microinjection of 100 or 200 µM nicotine into 
the pVTA resulted in extracellular DA increases of 300-330% above baseline in 
the NAc (Fig. 7).  aCSF microinjections in rats with either one of the adolescent 
treatments (saline or 0.5 mg/kg nicotine) did not result in any significant increase 
in extracellular DA levels in the NAc.  A repeated measures ANOVA was  
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Figure 7.  Time-course effects of microinjections (over 10 minutes) of 100 µM 
(triangles), 200 µM (circles), or aCSF (squares) on extracellular DA levels in the 
NAc of adult Wistar rats treated with 0.5 mg/kg nicotine (closed symbols) or 
saline (open symbols) during adolescence.  The closed squares represent all rats 
that received aCSF microinjections, regardless of adolescent treatment.  Data 
are expressed as percentages of baseline (mean + SEM).  No significant 
differences were observed. 
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performed on the percent increases in DA levels from baseline, with a repeated 
measure of Time and between-subjects factors of Adolescent Treatment and 
Microinjection Concentration.  Neither the 3-way interaction term (F8,30 = 0.659, p 
= 0.722) nor the individual main effects of Time (F4,14 = 1.518, p = 0.25), 
Adolescent Treatment (F1,17 = 3.714, p = 0.71), or Microinjection Concentration 
(F2,17 = 1.017, p = 0.383) were significant. 
 Due to the relatively low n in each group, especially the 100 µM 
microinjection group, and the similar percent increases in NAc DA levels resulting 
from 100 and 200 µM nicotine microinjections within each adolescent treatment 
group, data were collapsed across nicotine microinjection concentrations and 
analyzed by repeated measures ANOVA with a between-subject factor of 
Adolescent Treatment.  While the interaction term was not significant (F4,13 = 
0.978, p = 0.453), there was a significant main effect of Adolescent Treatment 
(F1,16 = 4.475, p = 0.050) (Fig. 8).  Paired t-tests indicated that for the first two 
post-injection time points, both of the Adolescent Treatment groups had 
extracellular DA levels in the NAc that were significantly increased above 
baseline (df = 8, p values < 0.05).  For the remaining post-injection time points, 
the NAc DA levels for the adolescent saline group were no longer significantly 
different from baseline (p values > 0.073).  NAc DA levels in the adolescent 0.5 
mg/kg nicotine group remained significantly elevated above baseline for the third 
and fourth time points (p values < 0.046), and were no longer significantly 




Figure 8.  Time-course effects of microinjections (over 10 minutes) of nicotine 
(100 or 200 µM) on extracellular DA levels in the NAc of adult Wistar rats treated 
with saline (closed circles) or 0.5 mg/kg nicotine (open circles) during 
adolescence.  Data are expressed as percentages of baseline (mean + SEM).   
* Indicates that that DA levels in the adolescent nicotine group were significantly 
higher than pre-injection baseline (p < 0.05).  ** Indicates that DA levels in both 
adolescent treatment groups were significantly higher than pre-injection baseline 




C.  Effects of adolescent nicotine exposure on adulthood behavioral sensitivity 
 to nicotine 
 
1.  Effects on subsequent baseline locomotor activity 
 
 The possibility that adolescent exposure to nicotine would influence 
baseline locomotor activity (LMA) during the initial period of exposure to the 
activity chamber was examined (Fig. 9).  A repeated measures ANOVA (within 
subject factor time, between subject factor adolescent pre-exposure) revealed a 
significant interaction of Adolescent Treatment x Time (F10,114 = 2.0, p = 0.04).  
Decomposing the interaction term by performing ANOVAs on activity segmented 
into 10-min bins revealed significant group effects during the first 40 min of the 
pre-injection hour (F2,60  values > 6.85: p values < 0.002).  Wistar rats treated 
with 0.5 mg/kg nicotine during adolescence had significantly higher LMA than 
rats treated with saline during all 4 time periods (Post-hoc comparisons, Tukey’s 
b); while rats treated with 0.25 mg/kg nicotine during adolescence had 
significantly higher LMA than control rats during the 2nd and 4th 10-min bin.  Rats 
that were treated with nicotine (0.25 or 0.5 mg/kg) during adolescence did not 
differ from each other during any time point.  The differences in baseline activity 
among the 3 groups were not observed during the last 20 min of the baseline 




Figure 9.  The mean (+ SEM) distances traveled in 10-min blocks during the 
initial 60 minutes, before any injections, in the locomotor activity chambers by 
Wistar rats that were treated with saline (closed circles, n=19), 0.25 mg/kg 
nicotine (open triangles, n=22), or 0.5 mg/kg nicotine (closed squares, n=22) 
during adolescence.  * Indicates that the groups that received 0.25 mg/kg or 0.5 
mg/kg nicotine were significantly (p < 0.05) different than the saline group. 
 56 
2.  Effects on locomotor sensitization 
 
 A repeated measures ANOVA on all rats revealed a significant Day x 
Adolescent Treatment x Adult Treatment interaction (F9,49 = 2.495, p = 0.02) 
across the 10 days of the LMA study.  The significant 3-way interaction was 
initially decomposed by holding adolescent treatment constant. 
 The effects of novel environment and initial (Day 1) adulthood nicotine 
treatment were examined (Fig. 10).  A one-way ANOVA indicated that novelty-
induced LMA in adulthood was affected by adolescent nicotine treatment (F2,60 = 
7.684, p = 0.001), with 25-40% higher LMA observed for the 2 groups exposed to 
nicotine during adolescence compared to the adolescent saline-treated group.  
For the initial adulthood injection of 0.25 or 0.5 mg/kg nicotine, significant 
differences in LMA were observed based on differing adolescent treatments (F2,19 
= 6.479 and 4.333, p = 0.007 and 0.028, respectively), with adult nicotine 
treatment producing a 2-fold greater stimulation in the groups exposed to nicotine 
during adolescence compared to the adolescent saline-treated rats.  Adolescent 
nicotine treatment did not have an effect on the LMA observed following an 
adulthood saline injection (F2,15 = 1.182, p = 0.334).   
A repeated measures ANOVA on the adult LMA data collected from rats 
treated with saline during adolescence did not reach significance, but showed a 
trend toward the expected overall effect of adult nicotine treatment (Fig. 11, top 
panel).  A priori hypothesis asserted that nicotine should increase LMA; 
therefore, individual ANOVAs were performed.  However, examining the overall 




Figure 10.  The mean (+ SEM) total distances traveled by Wistar rats during the 
60 minutes immediately preceding the first adulthood injection (left of dotted line, 
n = 19-22/group) and the 60 minutes following the first adulthood injection (right 
of dotted line, n = 6-8/group).  * Indicates that, in each respective grouping, the 
0.25 mg/kg and 0.5 mg/kg nicotine adolescent-treated groups were significantly 
(p < 0.05) different than the saline adolescent-treated group. 
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Figure 11.  The mean (+ SEM) total distances traveled across the 10 post-
injection locomotor activity sessions by adult Wistar rats that received (a) top 
panel, saline during adolescence (saline, 0.25 mg/kg nicotine, and 0.5 mg/kg 
nicotine in adulthood, n = 6-7/group); (b) middle panel, 0.25 mg/kg nicotine 
during adolescence (saline, 0.25 mg/kg nicotine, and 0.5 mg/kg nicotine in 
adulthood, n = 6-8/group), or (c) bottom panel, 0.5 mg/kg nicotine during 
adolescence (saline, 0.25 mg/kg nicotine, and 0.5 mg/kg nicotine in adulthood, n 
= 6-8/group).  Symbols and legend indicate drug treatment administered during 
the adulthood 10-day locomotor activity study.  * Indicates that the 0.5 mg/kg 
nicotine adult-treated group was significantly (p < 0.05) different than saline.  ** 
Indicates that the 0.25 mg/kg and 0.5 mg/kg nicotine adult-treated groups were 
significantly different than saline. 
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but between-group differences on Day 9 approached significance (F2,16 = 3.388, 
p = 0.059). 
 For the adolescent saline treated group, although significant differences in 
the total daily distances traveled were expected but not observed, differences did 
emerge when activity was reduced to 10-min blocks (Time x Adult Treatment: 
F5,13 = 10.472; p < 0.001).  Beginning on Test Day 3 (Fig. 12, top panel), rats 
treated with nicotine displayed an increase in LMA compared to saline treated 
rats during individual 10-min blocks; a significant effect of Adult Treatment (p < 
0.026) was observed during the 3rd and 4th 10-min blocks, with post hoc analyses 
revealing that the 0.25 and 0.5 mg/kg nicotine groups were different from saline 
controls.  On Day 6 (Fig. 13, top panel), for the adolescent saline treated group, 
there was a significant Time x Adult Treatment interaction (p = 0.046); individual 
ANOVA indicated a significant group difference during the 3rd bin  with post-hoc 
comparisons indicating that the 0.25 and 0.5 mg/kg nicotine groups were 
different from saline controls. During the 9th test session (Fig. 14, top panel), for 
the adolescent saline-treated rats, there was a significant effect of Adult 
Treatment (p < 0.023) during the 2nd and 3rd time period with post-hoc 
comparisons indicating that the 0.25 and 0.5 mg/kg nicotine groups were 
different from saline controls.   
A repeated measures ANOVA on the adult LMA data collected from rats 
treated with 0.25 mg/kg nicotine during adolescence (Fig. 11, middle panel) 
revealed a significant effect of Day (F9,11 = 4.482, p = 0.011) and a Day x Adult 




Figure 12.  The mean (+ SEM) distances traveled across the six 10-minute time 
blocks following injection on Day 3 by adult Wistar rats that received saline (top 
panel), 0.25 mg/kg nicotine (middle panel), and 0.5 mg/kg nicotine (bottom panel) 
during adolescence.  Symbols and legend indicate drug treatment administered 
during the adult portion of the study. * Indicates that the 0.25 mg/kg and 0.5 
mg/kg nicotine adult-treated groups were significantly (p < 0.05) different than 
saline.  ++ Indicates that the 0.5 mg/kg nicotine adult-treated group was 




Figure 13.  The mean (+ SEM) distances traveled across the six 10-minute time 
blocks following injection on Day 6 by rats that received saline (top panel), 0.25 
mg/kg nicotine (middle panel), and 0.5 mg/kg nicotine (bottom panel) during 
adolescence.  Symbols and legend indicate drug treatment administered during 
the adult portion of the study. # Indicates that the 0.25 mg/kg nicotine adult-
treated group was significantly (p < 0.05) different than saline.  ** Indicates that 
the 0.5 mg/kg nicotine adult-treated group was significantly different than saline.  
* Indicates that the 0.25 mg/kg and 0.5 mg/kg nicotine adult-treated groups were 




Figure 14.  The mean (+ SEM) distances traveled across the six 10-minute time 
blocks following injection on Day 9 by rats that received saline (top panel), 0.25 
mg/kg nicotine (middle panel), and 0.5 mg/kg nicotine (bottom panel) during 
adolescence.  Symbols and legend indicate drug treatment administered during 
the adult portion of the study.  * Indicates that the 0.25 mg/kg and 0.5 mg/kg 
nicotine adult-treated groups were significantly (p < 0.05) different than saline.  + 
Indicates that all three adult-treated groups were significantly different from each 
other.  ++ Indicates that the 0.5 mg/kg nicotine adult-treated group was 
significantly different than both other groups.  ** Indicates that the 0.5 mg/kg 
nicotine adult-treated group was significantly different than saline. 
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Post hoc analyses (Tukey’s b) revealed that the adults receiving 0.5 mg/kg 
nicotine showed significantly greater LMA than saline controls and 0.25 mg/kg 
nicotine on days 6 through 10.  
 Analysis of the individual 10-minute blocks within each 60-min activity 
session revealed more striking differences.  On Day 3 (Fig. 12, middle panel), for 
the group exposed to 0.25 mg/kg nicotine during adolescence, there was a 
significant effect of Adult Treatment (p = 0.033) during the 3rd time period with 
post hoc analyses indicating that the 0.5 mg/kg nicotine group was different from 
the saline and 0.25 mg/kg nicotine groups.  On the 6th test day (Fig. 13, middle 
panel), a significant effect of Adult Treatment (p < 0.036) was observed during 
the 2nd and 3rd time periods with post hoc analyses indicating that the 0.5 mg/kg 
nicotine group was higher than saline controls. On Day 9 (Fig. 14, middle panel), 
a significant overall Time x Adult Treatment interaction was observed (F5,16 = 
3.109, p = 0.038) for the adolescent 0.25 mg/kg nicotine-treated group, with post-
hoc comparisons revealing differences during all but the first and last 10-min 
blocks (p < 0.018).  Adult rats receiving 0.5 mg/kg nicotine showed significantly 
more locomotion than saline controls during the 4th and 5th blocks, and more than 
both the saline controls and 0.25 mg/kg nicotine group during the 3rd block.  
During the 2nd time block, all three groups were significantly different from each 
other. 
 A repeated measures ANOVA on the adult LMA data collected from rats 
treated with 0.5 mg/kg nicotine during adolescence (Fig. 11, bottom panel) 
revealed a significant effect of Day (F9,11 = 4.901, p = 0.008).  Post hoc analyses 
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(Tukey’s b) revealed that the adults receiving 0.25 mg/kg or 0.5 mg/kg nicotine 
showed significantly greater LMA than saline controls on days 4 through 9. 
 Analysis of the individual 10-min blocks within each 60-min activity 
session revealed that the group that received the 0.5 mg/kg adolescent dose of 
nicotine resulted in LMA differences.  On Day 3 (Fig. 12, bottom panel), a 
significant Adult Treatment (p < 0.027) was observed during the 3rd and 4th 10-
min blocks, with both the 0.25 and 0.5 mg/kg nicotine groups differing from saline 
controls.  On Day 6 (Fig. 13, bottom panel), for the adolescent 0.50 mg/kg 
nicotine-treated group, a significant overall Time x Adult Treatment interaction 
was observed (F5,16 = 3.305, p = 0.031), and post hoc analyses revealed that for 
the 2nd, 3rd and 4th time blocks, both nicotine groups were significantly higher 
than saline controls (p < 0.049).  On Day 9 (Fig. 14, bottom panel), a significant 
effect of Adult Treatment (p < 0.018) was observed for the adolescent 0.50 mg/kg 
nicotine exposed group, wherein the 0.5 mg/kg adult treatment was significantly 
higher than saline controls during the 3rd and 4th time periods, and higher than 
both the saline and 0.25 mg/kg groups during the 5th time period.  In the 2nd time 








D.  Effects of adolescent nicotine exposure on adulthood EtOH drinking 
 
1.  Initial EtOH intake 
 
 In order to study the effects of adolescent nicotine exposure, which 
concluded 35 days earlier, on initial EtOH drinking in adulthood, the EtOH intakes 
during the first 7 days of access were analyzed.  Differences in EtOH intake 
between groups can be noted even on the first day of EtOH access.  Wistar rats 
consumed 2-4 g/kg EtOH on the first day, whereas P rats, with access to 5% and 
10% EtOH, consumed 6-7 g/kg EtOH and P rats, with access to 15% and 30% 
EtOH, consumed 8-10 g/kg EtOH on the first day.   
 A repeated measures ANOVA on the daily EtOH intake averages by 
Wistar rats revealed a significant main effect of Day (F6,32 = 3.7, p = 0.007), but 
no significant main effect of Adolescent Treatment (F2,37 = 2.37, p = 0.108) or 
Day x Adolescent Treatment interaction term (F6,33 = 1.916, p = 0.107) (Fig. 15, 
top panel).   
 A repeated measures ANOVA on the daily EtOH intake averages by P 
rats, with access to 5% and 10% EtOH, revealed a significant main effect of Day 
(F6,12 = 3.7, p = 0.002), as well as a significant Day x Adolescent Treatment 
interaction (F6,13 = 4.406, p = 0.012), but no significant main effect of Adolescent 
Treatment (F2,17 = 0.477, p = 0.628)  (Fig. 15, middle panel).  However, post hoc 
analyses (Tukey’s b) did not indicate significant group differences on any 
individual day (F2,17 < 2.285 0.052, p values > 0.196).   
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Figure 15.  The mean (+ SEM) daily average EtOH intakes (g/kg/day) during the 
initial 7 days of continuous EtOH access by Wistar rats (top panel), P rats with 
access to 5% and 10% EtOH (middle panel), and P rats with access to 15% and 
30% EtOH (bottom panel).  Symbols indicate adolescent nicotine treatment with 
saline (closed circles), 0.25 mg/kg nicotine (open triangles), and 0.5 mg/kg 




In P rats drinking higher (15% and 30%) EtOH concentrations, a repeated 
measures ANOVA on the daily EtOH intake averages of the first 7 days of EtOH 
access revealed a significant main effect of Day (F6,9 = 6.606, p = 0.007), as well 
as a significant Day x Adolescent Treatment interaction (F6,10 = 46.011, p = 
0.007), but no significant main effect of Adolescent Treatment (F2,14 = 6.011, p = 
0.122) (Fig. 15, bottom panel).  Post hoc analyses did not indicate significant 
group differences on any individual day (F2,27 < 2.936, p values > 0.086). 
 
2.  Acquisition and maintenance of EtOH drinking behavior 
 
a.  Wistar rats 
The effects of adolescent nicotine exposure on EtOH intake by Wistar rats 
during the 8 weeks of continuous access were examined.  Of the 8 weeks of 
continuous EtOH access, the first 4 weeks are considered the acquisition phase 
of EtOH drinking behavior, and the second 4 weeks are considered the 
maintenance phase.  A repeated measures ANOVA on the weekly averages of 
the initial 4 weeks of EtOH drinking by Wistar rats revealed a significant Week x 
Adolescent Treatment interaction (F3,38 = 2.876, p = 0.049) (Fig. 16).  There were 
no significant main effects of Week (F3,37 = 1.944, p = 0.139) or Adolescent 
Treatment (F2,39 = 2.608, p = 0.086).  Post hoc analyses (Tukey’s b) revealed 
that for the 2nd and 3rd weeks of EtOH drinking, Wistar rats treated with 0.5 mg/kg 
nicotine during adolescence consumed significantly more EtOH than rats treated 




Figure 16.  The mean (+ SEM) average weekly EtOH intake amounts (g/kg/day) 
during the 8 weeks of continuous EtOH access by Wistar rats that were treated 
with saline (closed circles, n = 7), 0.25 mg/kg nicotine (open triangles, n = 8), or 
0.5 mg/kg nicotine (closed squares, n = 7) during adolescence.  * Indicates that 
rats in the 0.5 mg/kg group had higher intake than the saline group. 
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In addition to analyzing amount (g/kg of body weight) of EtOH consumed 
throughout the study, it is also important to investigate whether adolescent 
nicotine exposure had effects on preference for EtOH as a percentage of total 
fluid intake, as well as any differences in preference between the multiple 
concentrations of EtOH to which the rats had access.  In Wistar rats, repeated 
measures ANOVAs on the average weekly preference of 5% or 10% EtOH as a 
percentage of total fluid intake during either the 4 week acquisition period or the 
entire 8 weeks of continuous EtOH access indicated no significant main effects of 
Week (F3,16 < 2.071, p values > 0.128) or Adolescent Treatment (F3,16 < 3.434, p 
values > 0.104) or Adolescent Treatment x Week interactions (F3,17 < 3.434, p 
values > 0.186) (Fig. 17, top and middle panels).  However, there was a 
significant main effect of Week (F7,12 = 12.277, p < 0.001) on the preference for 
total EtOH (Fig. 17, bottom panel).  This indicates that, while there were no 
differences in preference for one of the two available EtOH concentrations over 
the 8 weeks of continuous EtOH access, there was an increase in EtOH intake 
as a percentage of total fluid intake for all groups of Wistar rats. 
 
b.  P rats – 5% and 10% EtOH 
Next, the effects of adolescent nicotine exposure on EtOH intake by P 
rats, with access to 5% and 10% EtOH, during the 8 weeks of continuous access 
were examined.  A repeated measures ANOVA on the 8 weeks of EtOH drinking 
revealed a significant main effect of Week (F7,11 = 6.967, p = 0.003) and a Week 




Figure 17.  The mean (+ SEM) average weekly intake of 5%, 10%, and total 
EtOH, expressed as a percentage of total fluid intake, by Wistar rats that were 
treated with saline (closed circles, n = 7), 0.25 mg/kg nicotine (open triangles, n = 
8), or 0.5 mg/kg nicotine (closed squares, n = 7) during adolescence.  No 




Figure 18.  The mean (+ SEM) average weekly EtOH intakes (g/kg/day) during 
the 8 weeks of continuous EtOH access by P rats, with access to 5% and 10% 
EtOH, that were treated with saline (closed circles, n = 8), 0.25 mg/kg nicotine 
(open triangles, n = 8), or 0.5 mg/kg nicotine (closed squares, n = 7) during 
adolescence.  * Indicates that the group that received 0.5 mg/kg nicotine is 
significantly (p < 0.05) different from the other groups. 
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was almost a significant main effect of Adolescent Treatment (F2,17 = 3.36, p = 
0.059).  The P rats treated with 0.5 mg/kg nicotine during adolescence had a 
tendency to have higher EtOH intakes than the saline group.  Post hoc analyses 
(Tukey’s b) revealed that for the second week of EtOH access, rats that were 
treated with 0.5 mg/kg nicotine during adolescence consumed significantly more 
EtOH than rats treated with 0.25 mg/kg nicotine or saline during adolescence (p 
= 0.025).   
Next, the EtOH preference data were analyzed using repeated measures 
ANOVAs on the 8 weeks of access to 5% and 10% EtOH.  For both 5% EtOH 
preference and total EtOH preference, a significant main effect of Adolescent 
Treatment was observed (F2,17 > 4.43, p values < 0.028) (Fig. 19, top and bottom 
panels).  Post hoc analyses (Tukey’s b) indicated that the rats treated with 0.5 
mg/kg nicotine during adolescence showed a significantly greater preference for 
5% EtOH during week 5 of EtOH access (p = 0.009), as well as a greater 
preference for total EtOH during the 3rd, 4th, and 5th weeks of EtOH access (p 
values < 0.045), compared to all other groups.  During the 7th week of EtOH 
access, both the 0.5 and 0.25 mg/kg nicotine treated groups showed a 
significantly greater preference for 5% EtOH than rats treated with saline (F2,17 = 
4.997, p = 0.02).  There was no significant effect of Adolescent Treatment on 




Figure 19.  The mean (+ SEM) average weekly intakes of 5%, 10%, and total 
EtOH, expressed as a percentage of total fluid intake, by P rats that were treated 
with saline (closed circles, n = 8), 0.25 mg/kg nicotine (open triangles, n = 8), or 
0.5 mg/kg nicotine (closed squares, n = 7) during adolescence.  * Indicates that 
the group that received 0.5 mg/kg nicotine is significantly (p < 0.05) different from 
the other groups.  ** Indicates that the saline group is significantly (p < 0.05) 
different from the other groups. 
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c.  P rats – 15% and 30% EtOH 
The effects of adolescent nicotine exposure on EtOH intake by P rats, with 
access to 15% and 30% EtOH, during the 8 weeks of continuous access were 
examined.  A repeated measures ANOVA on the 8 weeks of EtOH drinking 
revealed a significant main effect of Week (F7,8 = 4.682, p = 0.023), but no main 
effect of Adolescent Treatment and no significant interaction term, both on the 
initial 4 weeks and on the entire 8 weeks of continuous EtOH access (F14,18 < 
0.784, p values > 0.264) (Fig. 20).  Although the EtOH intake levels changed 
across the 8 weeks, there were no effects of adolescent nicotine treatment on 
EtOH intake. 
 Repeated measures ANOVAs on the preference for 15%, 30%, or total 
EtOH as a percentage of total fluid intake across the 8 weeks of acquisition and 
maintenance of EtOH drinking revealed significant main effects of Week for both 
15% and 30% preference (F7,8 > 4.558, p values < 0.025) (Fig. 21, top and 
middle panels).  However, there was no significant main effect of Week on total 
EtOH preference (F7,8 = 2.298, p = 0.133) (Fig. 21, bottom panel), and no 
significant main effects of Adolescent Treatment on preference for 15% or 30% 




Figure 20.  The mean (+ SEM) average weekly EtOH intakes (g/kg/day) during 
the 8 weeks of continuous EtOH access by P rats, with access to 15% and 30% 
EtOH, that were treated with saline (closed circles, n = 10), 0.25 mg/kg nicotine 
(open triangles, n = 10), or 0.5 mg/kg nicotine (closed squares, n = 10) during 





Figure 21.  The mean (+ SEM) average weekly intakes of 15%, 30%, and total 
EtOH, expressed as a percentage of total fluid intake, by P rats that were treated 
with saline (closed circles, n = 10), 0.25 mg/kg nicotine (open triangles, n = 10), 
or 0.5 mg/kg nicotine (closed squares, n = 10) during adolescence.  There were 
no significant differences. 
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3.  Relapse EtOH drinking 
 
a.  Wistar rats 
 The possibility that adolescent nicotine exposure may have altered 
relapse EtOH drinking in Wistar rats was examined.  To assess whether 
adolescent nicotine exposure altered EtOH relapse drinking following the first 
EtOH deprivation, a repeated measures ANOVA was performed on the pre-
deprivation baseline and first 4 EtOH re-exposure days, with repeated measures 
of Day and a between-subject factor of Adolescent Treatment.  This ANOVA 
indicated a significant main effect of Day (F5,14 = 6.438, p = 0.003), but no 
significant main effect of Adolescent Treatment (F2,18 = 0.277, p = 0.761) or 
interaction term (F10,30 = 0.746, p = 0.677).  Next, paired t-tests indicated that all 
groups of rats showed significantly greater EtOH intake on the first three re-
exposure days compared to the pre-deprivation baseline (df = 14, p values < 
0.015) (Fig. 22).  By the 4th re-exposure day, EtOH intake was not significantly 
different from the pre-deprivation baseline (df = 14, p values > 0.11).  However, a 
one-way ANOVA indicated no significant differences between adolescent 
nicotine groups on either the pre-deprivation baseline or any of the re-exposure 
days (F2,39 < 0.784, p values > 0.46). 
Two additional cycles of 2-week EtOH deprivations and 2-week EtOH 
reinstatements were performed.  All Wistar rats consumed significantly more 
EtOH in the days following the deprivations as compared to the respective pre-




Figure 22.  The mean (+ SEM) average daily EtOH intakes (g/kg/day) preceding 
and following a 2-week EtOH deprivation by Wistar rats treated with saline (open 
bars, n = 7), 0.25 mg/kg nicotine (gray bars, n = 8), and 0.5 mg/kg nicotine (black 
bars, n = 7) during adolescence.  Baseline EtOH intake levels (left of dotted line) 
were taken as the average daily EtOH intake during the week immediately 
preceding the deprivation.  * Indicates all nicotine treatment groups are 
significantly (p < 0.05) different than baseline. 
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cycle, however there were no effects of adolescent nicotine exposure on the 
relapse EtOH drinking in either of these cycles (data not shown). 
 Next, preference for 5%, 10%, and total EtOH during the cycles of EtOH 
deprivation and reinstatement were analyzed using repeated measures 
ANOVAs.  Following the first EtOH deprivation, there were no significant main 
effects of Adolescent Treatment on the preferences for 5% or 10% EtOH or for 
EtOH as a percentage of total fluid intake (F5,14 < 2.284, p values > 0.099) (Fig. 
23). Following the second EtOH deprivation, however, analysis of the preference 
for both 5% and 10% EtOH revealed a significant Day x Adolescent Treatment 
interaction (F5,15 > 2.781, p values < 0.047) (Fig. 24, top and middle panels), and 
a significant main effect of adolescent treatment was observed on preference for 
10% EtOH (F2,18 = 6.715, p = 0.007) (Fig. 24, middle panel).  Interestingly, post-
hoc analyses (Tukey’s b) indicated that the rats treated with saline showed a 
significantly greater preference for 10% EtOH than nicotine-treated rats on all but 
the 4th reinstatement day (F2,18 > 5.165, p values < 0.017).  No significant effects 
of adolescent nicotine treatment on total EtOH preference were observed (Fig. 
24, bottom panel).   
Finally, following the third EtOH deprivation, a significant main effect of 
Adolescent Treatment was observed in the preference for 10% EtOH (F2,18 = 
3.995, p = 0.037) (Fig. 25, middle panel), but no significant effects of Adolescent 
Treatment were observed in preference for 5% EtOH or total EtOH (F4,16 < 1.63, 




Figure 23.  The mean (+ SEM) average daily intake of 5%, 10%, and total EtOH, 
expressed as a percentage of total fluid in take, preceding and following the first 
2-week EtOH deprivation period by Wistar rats treated with saline, 0.25 mg/kg 





Figure 24.  The mean (+ SEM) average daily intake of 5%, 10%, and total EtOH, 
expressed as a percentage of total fluid in take, preceding and following the 
second 2-week EtOH deprivation period by Wistar rats treated with saline, 0.25 
mg/kg nicotine, and 0.5 mg/kg nicotine during adolescence.  + Indicates that the 
adolescent saline group is significantly (p < 0.05) different from the other groups.  
++ Indicates that the adolescent saline group is significantly (p < 0.05) different 




Figure 25.  The mean (+ SEM) average daily intake of 5%, 10%, and total EtOH, 
expressed as a percentage of total fluid in take, preceding and following the third 
2-week EtOH deprivation period by Wistar rats treated with saline, 0.25 mg/kg 
nicotine, and 0.5 mg/kg nicotine during adolescence.  No significant differences 
between nicotine treatment groups were observed. 
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saline-treated rats that showed a greater preference for 10% EtOH than the other 
two groups following the third EtOH deprivation. 
  
b.  P rats – 5% and 10% EtOH 
 The possibility that adolescent nicotine exposure may have altered 
relapse EtOH drinking in P rats, with access to 5% and 10% EtOH, was 
examined.  To assess whether adolescent nicotine exposure altered EtOH 
relapse drinking following the first EtOH deprivation, a repeated measures 
ANOVA was performed on the pre-deprivation baseline and first 4 EtOH re-
exposure days, with repeated measures of Day and a between-subject factor of 
Adolescent Treatment.  This ANOVA indicated a significant main effect of Day 
(F4,14 = 23.047, p < 0.001), but no significant main effect of Adolescent Treatment 
(F2,17 = 0.835, p = 0.731) or interaction term (F8,30 = 0.792, p = 0.614).  Paired t-
tests indicated that all groups of rats showed a significant increase in EtOH 
intake on the first re-exposure day compared to the pre-deprivation baseline (df = 
19, p = 0.002) (Fig. 26).  By the second re-exposure day, EtOH intake was not 
significantly different from the pre-deprivation baseline (p = 0.499).   However, a 
one-way ANOVA indicated no significant differences between adolescent 
nicotine groups on either the pre-deprivation baseline or any of the re-exposure 
days (F2,17 > 0.039, p values > 0.301).   
Two additional cycles of 2-week EtOH deprivations and 2-week EtOH 
reinstatements were performed.  All P rats consumed significantly more EtOH in 




Figure 26.  The mean (+ SEM) average daily EtOH intakes (g/kg/day), preceding 
and following a 2-week EtOH deprivation by P rats with access to 5% and 10% 
EtOH, treated with saline (open bars, n = 8), 0.25 mg/kg nicotine (gray bars, n = 
8), and 0.5 mg/kg nicotine (black bars, n = 7) during adolescence.  Baseline 
EtOH intake levels (left of dotted line) were taken as the average daily EtOH 
intake during the week immediately preceding the 2-week EtOH deprivation 
period.  * Indicates that EtOH intakes in all three groups are significantly (p < 
0.05) different than baseline. 
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baselines, however there were no effects of adolescent nicotine exposure on the 
relapse EtOH drinking in either of these cycles (data not shown). 
 Next, the effects of adolescent nicotine treatment on EtOH preference 
were analyzed using repeated measures ANOVAs.  Following the first EtOH 
deprivation period, a significant main effect of Adolescent Treatment was 
observed on both 5% and 10% EtOH preference (F1,18 > 4.307, p values < 0.031) 
(Fig. 27, top and middle panels).  When looking at total EtOH preference, no 
differences were observed (F2,17 = 2.639, p = 0.10), although it should be noted 
that all groups of rats were drinking almost exclusively EtOH during the first few 
days of reinstatement of EtOH access (Fig. 27, bottom panel).  Following the 
second and third EtOH deprivations, no significant main effects of Day (F5,14 < 
2.532, p values > 0.082) or Adolescent Treatment (F2,17 < 2.653, p values > 
0.121) on preference for 5%, 10%, or total EtOH were observed (Figs. 28 and 
29). 
 
c.  P rats – 15% and 30% EtOH 
 Finally, the effects of adolescent exposure on relapse EtOH drinking were 
examined in P rats with access to higher concentrations (15% and 30%) of EtOH.  
A repeated measures ANOVA performed on the pre-deprivation baseline and 
first 4 EtOH re-exposure days indicated a significant main effect of Day (F4,24 = 
23.917, p < 0.001), but no significant main effect of Adolescent Treatment (F2,27 = 
0.285, p = 0.754) or interaction term (F8,50 = 0.322, p = 0.954).  Paired t-tests 




Figure 27.  The mean (+ SEM) average daily intakes of 5%, 10%, and total 
EtOH, expressed as a percentage of total fluid intake, preceding and following 
the first 2-week EtOH deprivation period by P rats treated with saline, 0.25 mg/kg 
nicotine, and 0.5 mg/kg nicotine during adolescence.  * Indicates that the 0.5 
mg/kg nicotine group is significantly (p < 0.05) different from the saline group.   
** Indicates that the 0.5 mg/kg nicotine group is significantly (p < 0.05) different 




Figure 28.  The mean (+ SEM) average daily intake of 5%, 10%, and total EtOH, 
expressed as a percentage of total fluid intake, preceding and following the 
second 2-week EtOH deprivation period by P rats treated with saline, 0.25 mg/kg 





Figure 29.  The mean (+ SEM) average daily intakes of 5%, 10%, and total 
EtOH, expressed as a percentage of total fluid intake, preceding and following 
the third 2-week EtOH deprivation period by P rats treated with saline, 0.25 
mg/kg nicotine, and 0.5 mg/kg nicotine during adolescence.  No significant 
differences were observed. 
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first re-exposure day (df = 29, p < 0.001) (Fig. 30).  By the second re-exposure 
day, EtOH intake levels did not differ from the pre-deprivation baseline (p = 
0.130).  A one-way ANOVA indicated no significant differences between 
adolescent nicotine groups on either the pre-deprivation baseline or any of the 
re-exposure days (F2,27 < 0.789, p values > 0.465). 
Two additional cycles of 2-week EtOH deprivations and 2-week EtOH 
reinstatements were performed with these rats.  All P rats consumed significantly 
more EtOH in the days following the deprivations as compared to the respective 
pre-deprivation baselines, however there were no effects of adolescent nicotine 
exposure on the relapse EtOH drinking in either of these cycles (data not shown). 
 The effects of adolescent nicotine treatment on EtOH preference were 
analyzed using repeated measures ANOVAs for each of the 3 deprivations (Figs. 
31-33).  Following all 3 EtOH deprivations, significant main effects of Day (F5,10 < 
3.681, p values > 0.038) were observed on preference for each 15%, 30%, and 
total EtOH, but there were no significant main effects of Adolescent Treatment 
(F2,14 < 1.278, p values > 0.309) on preference for 15%, 30%, or total EtOH. 
 
4.  Effects of nicotine exposure during adulthood 
 
 In order to assess whether any observed effects of adulthood EtOH 
drinking were correlated with nicotine exposure specifically during adolescence, 




Figure 30.  The mean (+ SEM) average daily EtOH intakes (g/kg/day) preceding 
and following a 2-week EtOH deprivation by P rats with access to 15% and 30% 
EtOH, treated with saline (open bars, n = 10), 0.25 mg/kg nicotine (gray bars, n = 
10), and 0.5 mg/kg nicotine (black bars, n = 10) during adolescence.  Baseline 
EtOH intake levels (left of dotted line) were taken as the average daily EtOH 
intake during the week immediately preceding each 2-week EtOH deprivation 
period.  * Indicates that EtOH intakes in all three groups are significantly (p < 




Figure 31.  The mean (+ SEM) average daily intakes of 15%, 30%, and total 
EtOH, expressed as a percentage of total fluid intake, preceding and following 
the first 2-week EtOH deprivation period by P rats treated with saline, 0.25 mg/kg 





Figure 32.  The mean (+ SEM) average daily intakes of 15%, 30%, and total 
EtOH, expressed as a percentage of total fluid intake, preceding and following 
the second 2-week EtOH deprivation period by P rats treated with saline, 0.25 
mg/kg nicotine, and 0.5 mg/kg nicotine during adolescence.   No significant 




Figure 33.  The mean (+ SEM) average daily intakes of 15%, 30%, and total 
EtOH, expressed as a percentage of total fluid intake, preceding and following 
the third 2-week EtOH deprivation period by P rats treated with saline, 0.25 
mg/kg nicotine, and 0.5 mg/kg nicotine during adolescence.  No significant 
differences were observed. 
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from PD 60-71 and then given subsequent 24-hour access to 5% and 10% EtOH 
beginning on PD 110.  A repeated measures ANOVA on the EtOH intake during 
the initial 7 days of access revealed no significant main effects of Day (F6,7 = 
0.947, p = 0.518) or Treatment (F1,12 = 0.253, p = 0.624).  A repeated measures 
ANOVA on the EtOH intake of this control group of Wistar rats showed a 
significant main effect of Week (F7,6 = 5.517, p = 0.027) but no significant effect 
of Treatment (F1,12 = 0.09, p = 0.77) or significant interaction term (F7,6 = 0.548,p 
= 0.775) during the 8-week period of continuous EtOH access (Fig. 34).   
 
5.  Water intake 
 
The possibility that adolescent nicotine exposure may have influenced 
water intake during adulthood was investigated.  A repeated measures ANOVA 
on the water in take of Wistar rats during the initial 7 days of EtOH access 
revealed no significant main effects of Day (F6,7 = 0.947, p = 0.518) or 
Adolescent Treatment (F1,12 = 0.253, p = 0.624).  A repeated measures ANOVA 
on the water intake during the 8-week period of continuous EtOH access 
revealed a significant main effect of Week (F4,36 = 2.749, p = 0.043) but no 
significant effects of Adolescent Treatment (F2,39 = 2.548, p = 0.091).  During the 
1st week of EtOH access, all groups consumed approximately 30-35 g/day of 
water, and by the 4th week, average water consumption was reduced to 




Figure 34.  The mean (+ SEM) average weekly EtOH intakes (g/kg/day) during 
the 8 weeks of continuous EtOH access by a group of Wistar rats that were 
previously treated with saline (closed circles, n = 7), or 0.5 mg/kg nicotine (open 
triangles, n = 7) during adulthood.  The mean (+ SEM) average daily EtOH intake 
amounts for the initial 7 days of EtOH access are depicted in the inset.  No 
significant differences were observed. 
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shown) was not unexpected, due to the increase of EtOH intake by all rats over 
time, especially during the initial 4 weeks of EtOH access. 
 Next, the effects of adolescent nicotine exposure on adulthood water 
intake in P rats with access to 5% and 10% EtOH were examined.  A repeated 
measures ANOVA on the water in take during the initial 7 days of EtOH access 
revealed no significant main effects of Day (F6,12 = 2.681, p = 0.069) or 
Adolescent Treatment (F2,17 = 1.127, p = 0.347).  A repeated measures ANOVA 
on the water intake during the 8-week period of continuous EtOH access 
revealed a significant main effect of Week (F4,14 = 3.573, p = 0.033) but no 
significant effects of Adolescent Treatment (F2,17 = 3.428, p = 0.056).  During the 
1st week of EtOH access, all groups consumed approximately 9-12 g/day of 
water, and by the 4th week, average water consumption was reduced to 
approximately 4-9 g/day. 
 Finally, the effects of adolescent nicotine exposure on adulthood water 
intake in P rats with access to 15% and 30% EtOH were examined.  A repeated 
measures ANOVA on the water in take during the initial 7 days of EtOH access 
revealed a significant main effect of Day (F6,9 = 13.09, p = 0.001), but no 
significant main effect of Adolescent Treatment (F2,14 = 0.256, p = 0.778).  A 
repeated measures ANOVA on the water intake during the 8-week period of 
continuous EtOH access revealed no significant main effects of Week (F7,8 = 
1.679, p = 0.241) or Adolescent Treatment (F2,14 = 0.667, p = 0.529).  During the 
1st week of EtOH access, all groups consumed approx. 22-24 g/day of water, 
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and by the 4th week, average water consumption remained relatively unchanged 
at approximately 23-25 g/day. 
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IV.  DISCUSSION 
 
A. The pVTA is a neuroanatomical site that supports nicotine reinforcement 
 
In the first part of this dissertation, it was investigated whether nicotine 
would be self-administered directly into the pVTA by Wistar rats, since this is a 
neuroanatomical site known to support self-infusion of other drugs of abuse, and 
also a region where nAChRs are highly localized.  The primary finding of the first 
aim of this dissertation is that that Wistar rats initiated and maintained intracranial 
self-administration (ICSA) of nicotine into the pVTA in a dose-dependant manner 
(Figs. 2 and 3).  The average numbers of self-infusions into areas surrounding 
the pVTA, including the SNr, SNc, and RN, were low (< 15 infusions per session) 
(Fig. 4), which indicates that the reinforcing effects of nicotine in the pVTA are 
not likely due to diffusion of the drug into adjacent areas.  Although the aVTA 
was not specifically tested in this study, previous studies have demonstrated that 
it is not a site mediating the reinforcing properties of nicotine (Ikemoto et al. 
2006) or EtOH (Rodd-Henricks et al. 2000a).  Taken together, these results 
indicate that the pVTA is a neuroanatomical site responsible for mediating the 
rewarding properties of nicotine in the central nervous system.  The study of 
specific sites involved in nicotine reinforcement should be expanded in the future.  
Such further studies should include the aVTA, but based on previous research, it 
would be hypothesized that the aVTA would not be a site that mediates nicotine 
reinforcement. 
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 With any self-administration study, there is the concern that observed 
increases in lever responding may be due to elevations in locomotor activity, 
rather than motivational stimulus effects of the drug.  Here, the self-
administration of nicotine into the pVTA did not appear to be a result of a general 
increase in locomotor activity, because the rats readily discriminated between the 
active and inactive levers for the self-infusion of 10 - 400 µM nicotine.  
Additionally, across all nicotine doses, when aCSF was substituted for nicotine 
during the extinction sessions (sessions 5 and 6), responses on the active lever 
decreased toward the levels of those on the inactive lever.  Finally, greater 
responding on the active lever was reinstated when nicotine was restored during 
session 7. 
 Looking closer at the between sessions lever pressing patterns (Fig. 3) 
reveals some interesting observations.  In rats responding for 10 µM nicotine, the 
number of active lever presses was similar to that of the rats responding for 
aCSF throughout the experiment; however, the rats responding 10 µM for 
nicotine showed significant lever discrimination in acquisition sessions 1-3 and in 
the reinstatement (7th) session.  This indicates that while the low dose of nicotine 
may not have been highly reinforcing (compared to the higher doses of nicotine), 
it has reinforcement salience; that is, the rats were able to detect and 
differentiate between infusions of 10 µM nicotine and aCSF in the pVTA. 
 With some nicotine doses, inactive lever presses were initially high.  For 
example, the rats self-infusing 50 µM nicotine responded 30-50 times on the 
inactive lever during each of the first 3 sessions.  However, by the 4th session, 
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inactive lever pressing was low (< 15 responses per session), and remained low 
throughout the remainder of the sessions.  A similar pattern of responding on the 
inactive lever was observed in the rats self-infusing 200 and 400 µM nicotine.  It 
is possible that this relatively high level of inactive lever pressing was due to 
locomotor activation by nicotine, which has been widely reported as an effect of 
systemic (Clarke and Kumar 1983a and 1983b; Clarke et al. 1988) and local 
intra-VTA (Leikola-Pelho and Jackson, 1992) nicotine treatment.  However, even 
when inactive lever responding was high, the rats self-infusing 50, 200, and 400 
µM discriminated between the active and inactive levers.  Thus, nicotine seems 
to have reinforcement saliency in rats even when they are behaviorally activated 
by the drug’s locomotor effects. 
 Interestingly, the rats self-administering the 100 µM dose of nicotine did 
not demonstrate the relatively high level of inactive lever responding in the early 
sessions that was seen in the groups self-administering 50, 200, or 400 µM 
nicotine.  In this group, the number of inactive lever presses was below 25 per 
session across all 7 sessions.  It is unknown why this group did not demonstrate 
the initially higher inactive lever responding like the other groups.  In the first 
ICSA session, the 100 µM nicotine group also showed a relatively low number of 
active lever responses (approx. 30-35, not significantly different from active lever 
responses by rats self-infusing aCSF) and did not discriminate between levers, 
and the reason for this is also unknown.  However, following that first session, 
rats in this group discriminated between the active and inactive levers, so it 
seems as though the initial session was the only aberrant one. 
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 In the group of rats self-infusing 800 µM nicotine, lever discrimination was 
observed in the first session and then was not present during the rest of the 
sessions in which nicotine was available.  Additionally, active lever responding 
declined across the sessions, and did not differ from active lever responding in 
the aCSF group in sessions 4-7.  This indicates that the 800 µM dose of nicotine 
was not as rewarding as the 50-400 µM doses, and may have even had aversive 
properties.  Thus, one can conclude that the dose-response pattern of nicotine in 
the pVTA is an inverted U-shaped curve, as depicted in Fig. 2. 
 Analyses on the extinction (sessions 4-6) and reinstatement (sessions 5-
7) of active lever responding revealed that the response-contingent behavior was 
significantly extinguished only in the 10, 100, and 200 µM nicotine groups, and 
significantly reinstated only in the 10 µM nicotine group.  It is likely that between-
subject variability in each nicotine dose group was the reason why statistically 
significant extinction and reinstatement were not seen in other groups.  However, 
looking at Fig. 3, one can see the tendency for active lever responding to decline 
during the extinction sessions and increase in the reinstatement session, 
especially in the 50-400 µM nicotine groups. 
 When injector cannulae were aimed at areas adjacent to the pVTA, the 
numbers of nicotine infusions were low (< 15 infusions per session, Fig. 4) and 
active lever responses were also low (< 30 lever presses per session, Fig. 5), 
compared to the data from rats self-infusing nicotine into the pVTA.  While there 
were no significant differences among injector placement groups during sessions 
3 and 4 of the ICSA experiment, rats self-infusing nicotine into the RN appeared 
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to show a lower level of infusions than rats self-infusing nicotine into the SNc 
(Fig. 4).  In fact, the number of infusions approached zero on these days.  The 
RN is involved in motor coordination and has no connectivity to the mesolimbic 
DA pathway or any other pathways known to be involved in reward, so the low 
number of infusions may have been due to motor effects. 
 The finding that nicotine is reinforcing within the pVTA is consistent with 
previous studies demonstrating that nicotine’s reinforcing effects are mediated by 
the mesolimbic DA neurons projecting from the pVTA to the shell of the nucleus 
accumbens (Corrigall et al. 1992; Ikemoto and Wise 2002).  Additionally, other 
drugs of abuse such as ethanol and morphine have been shown to be reliably 
self-infused into the pVTA of rats (Rodd-Henricks et al. 2000a; Devine and Wise 
1994).  One previous study by Ikemoto et al. (2006) demonstrated dose-
dependent self-infusion of nicotine into ventral midbrain areas including the pVTA 
as well as the supramammillary nucleus and the central linear nucleus, although 
the doses used were in the mM range (12.5-50 mM) and therefore approximately 
1000-fold higher than the doses examined in the current study.  Considering that 
pharmacologically relevant brain concentrations of nicotine in human cigarette 
smokers is in the 100-500 nM range (Karan et al. 2003), the doses from the 
aforementioned previous study are much higher than what would be 
physiologically relevant in humans, and therefore difficult to compare with the 
results of the current study.  Higher concentrations of nicotine would be more 
likely to diffuse from the microinjection site to other nearby brain regions, which 
complicates the interpretation of the results.   
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Differences in study design also exist.  In our study, each rat was given 
the opportunity to self-infuse only one concentration of nicotine during the four 
acquisition sessions and the final reinstatement session.  In the Ikemoto study, 
each rat self-administered a variety of nicotine concentrations, starting with high 
ones (12.5-50 mM) and concluding with some in a lower range (0.1-10 mM).  
Therefore, order effects have possibly complicated the expression of response-
contingent behavior.  This is further complicated by the use of only one extinction 
session (during which only vehicle was infused upon active lever pressing) was 
used between the high-dose and lower-dose phases.  Results from the current 
study show that, for some doses, extinction of active lever pressing is not fully 
extinguished until the second drug-free session.  However, while some 
methodological differences exist, the finding that nicotine is self-administered into 
the pVTA and not areas adjacent to the VTA is supported by Ikemoto’s previous 
study. 
 The lower levels of infusions and active lever responses by rats with 
injector cannulae in the SN subregions and RN as compared to the pVTA may be 
due to a lesser ability of nicotine to activate neurons originating in these areas.  
Although nicotine was shown to activate neurons in the SN in 
electrophysiological studies (Clarke et al. 1985), a later study showed that 
nicotine-elicited currents in DA neurons originating in the VTA were significantly 
larger than those in SNc dopaminergic projections (Klink et al. 2001).  
Unfortunately, that particular study did not differentiate between currents 
originating in the SNc or SNr.  Ikemoto’s (2006) study also concluded that 
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nicotine was not self-administered into the SN.  So, while nAChRs are present in 
the SN, it spears that nicotine activation of these nAChRs is not reinforcing.  
The inverted U-shaped dose response curve could be explained by 
nicotinic modulation of both GABAergic and glutamatergic input to DA neurons 
within the VTA, which was mentioned in the Introduction section of this 
dissertation.  Nicotine infused locally into the VTA could bind to nAChRs on any 
of three different types of neurons: directly on VTA DA neurons via nAChRs, 
most of which are of the high-affinity non-α7 variety; GABA interneurons within 
the VTA, which also express primarily non-α7 nAChRs; and presynaptic nAChRs 
on glutamatergic terminals, most of which are the low-affinity α7-containing 
variety (Pidoplichko et al. 1997; Klink et al. 2001).  At the lowest concentrations 
tested here, nicotine was not self-administered at a rate greater than that of 
aCSF.  Therefore, it is possible that the nAChRs activated by these lowest 
concentrations were primarily the high-affinity non-α7-containing ones on the DA 
and GABA neurons, and that the net result of DA neuron activation and 
GABAergic inhibition was not sufficient to result in reinforcement for the rats.  At 
the doses that supported response-contingent behavior and lever discrimination 
(100-400 µM), it is more likely that the low-affinity α7-containing nAChRs on the 
presynaptic glutamatergic terminals would have also been activated, thereby 
providing enough additional excitatory input for the summation of signaling from 
all three neuron types to potentiate activation of the mesoaccumbens DA 
neurons, even in the wake of desensitization of the high-affinity non-α7-
containing nAChRs on the DA and GABA neurons.  At these concentrations, 
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desensitization of the non-α7 nAChRs on the DA and GABA neurons may come 
into play, which would make the excitatory glutamatergic input onto the pathway 
all the more important.  Finally, at the highest nicotine concentrations tested, 
even the low-affinity α7 nAChRs on the glutamate terminals may have become 
desensitized, shifting the mesoaccumbens pathway back to a state which was 
not reinforcing to the rats.  
A study of nicotine ICSA has also been performed in mice (David et al. 
2006).  The paradigm was different from the current study in that the self-
infusions were triggered by successful completion of a Y-maze, which makes it a 
preference-based paradigm that was not dependent on rate of responses.  As 
such, the results are not directly comparable to those of the current ICSA study.  
However, the results from this previous study are important because they confirm 
that the VTA is a region that supports nicotine reinforcement.  Additionally, they 
show that the competitive nAChR antagonist DHBE, when co-infused with 
nicotine, rapidly and significantly decreased the ICSA response.  Since DHBE is 
selective for the α4β2 nAChRs, this study supports the idea that this nAChR 
subtype is crucial for nicotine reinforcement.  This finding was in agreement with 
an earlier study showing that mutant mice lacking the β2 subunit of the nAChR 
showed impaired i.v. nicotine self-administration and nicotine-stimulated NAc DA 
release (Picciotto et al. 1998). 
Building on this information about the β2 subunit, a recent study used 
mutant mice to ascertain the role of different α subunits in the VTA on systemic 
nicotine self-administration (Pons et al. 2008).  β2 subunits are known to 
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combine most commonly in the VTA with α4 subunits, although they are found to 
a lesser extent in combination with α6 subunits.  Genetic knockout (KO) mice 
missing each of these individual subunits, plus an α7 KO and the wild-type 
mouse, were tested for acquisition of i.v. nicotine self-administration.  Pons and 
colleagues reported that self-administration was promptly acquired by the WT 
and α7 KO mice, but not the mice missing the α4 or α6 subunits.  Additionally, 
when viral vectors were used to re-express the missing α4 or α6 subunits 
specifically in the VTA in the KO mice, they acquired nicotine self-administration. 
β2 KO mice also did not self-administer nicotine, until the β2 subunit was virally 
re-expressed in the VTA.  Re-expression of β2 in the SN, however, did not result 
in nicotine-self administration.  Together, these results show that α4β2 and α6β2 
-containing nAChRs, but not α7-containing nAChRs, must be present specifically 
in the VTA for nicotine self-administration to take place.  
Although this previous study didn’t indicate a role for α7-containing 
nAChRs in nicotine reward, other work has done so.  For example, intra-VTA 
administration of nicotine was shown to be rewarding in a conditioned place 
preference procedure (Laviolette and van der Kooy 2003a).  When the α7-
nACHR-selective antagonist methyllycaconitine (MLA) was co-infused with 
nicotine, the motivational valence was switched from rewarding to aversive.   
To summarize this section, the study performed here demonstrates that 
rats will reliably self-administer nicotine directly into the pVTA in a dose-
dependant manner, and that sites adjacent to the pVTA do not support nicotine 
self-administration behavior.  These results pinpoint the pVTA as an important 
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neuroanatomical substrate for the reinforcing properties of nicotine.  Results from 
earlier studies indicate that the reinforcing action of nicotine in the pVTA seen 
here is likely predicated on activation of α4β2 and α6β2 -containing nAChRs, 
although, as discussed in this section and in the Introduction, it is probable that 
α7 homopentameric nAChRs are involved in the local reinforcing actions of 
nicotine as well.   
 
B.  Adolescent exposure to nicotine results in persistent changes in the 
mesolimbic DA system 
 
 The second and third aims of this dissertation were to assess the 
persistent effects of adolescent nicotine exposure on the mesolimbic DA system 
both neurobiologically and behaviorally.  Using the finding from the first aim that 
the pVTA is a neuroanatomical site that mediates the reinforcing properties of 
nicotine, and based on earlier work demonstrating that systemic nicotine self-
administration increases DA output in the NAc shell to a greater extent than in 
the NAc core (Lecca et al. 2006), here we examined the effects of a series of 
intra-pVTA microinjections on DA release within the shell of the NAc in rats that 
either did or did not receive repeated injections of nicotine during adolescence.  
The microinjection procedure was set up to mimic a pattern of infusions that a rat 
might self-administer in our ICSA paradigm, so as to provide insight into the 
conditions that may be present during the response-contingent behavior.   
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The major finding of the second aim of this dissertation was that exposure 
to nicotine during adolescence resulted in enhanced nicotine-stimulated DA 
release in the shell of the NAc during adulthood.  This enhancement was 
predicated on increases in both the amplitude and the duration of increased DA 
release (Fig. 8).  Following the 10-minute series of microinjections of either 100 
or 200 µM nicotine into the pVTA, DA levels in the NAc shell increased to 
approximately 150% of pre-injection baseline amounts in the rats treated with 
saline during adolescence.  By the 3rd post-injection time point, 60 minutes 
following the injection, DA levels in the NAc were no longer significantly different 
from baseline in these rats.  In the rats treated with nicotine during adolescence, 
however, DA levels in the NAc were elevated approx. 300% above pre-injection 
baseline in the 20 minutes following the nicotine microinjection, which is a 
significant increase above the baseline for this group.  At the second post-
injection time point, DA levels in the adolescent nicotine rats remained 
significantly higher than pre-injection baseline, by approximately 200%.  DA 
levels remained elevated above baseline for 80 minutes after the pVTA nicotine 
injection in this group, and returned to baseline levels at 100 minutes post-
injection.   
 The finding that intra-VTA nicotine microinjections result in increases in 
DA in the NAc is consistent with the overall idea that drug reinforcement is 
predicated on accumbal DA release.  Since the first part of this dissertation 
demonstrated that nicotine is reinforcing within the pVTA, it was expected that 
pVTA microinjections would induce DA release in the NAc.  The current findings 
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are also supported by previous studies showing extracellular DA elevations in the 
NAc following systemic nicotine administration, through intravenous, 
subcutaneous, and central means, and at doses known to support self-
administration in rats (Pontieri et al. 1996; Benwell and Balfour 1992; Tizabi et al. 
2002).  The current study serves to pinpoint the pVTA as a specific site 
regulating this neurobiological effect.  Further support for the current results 
comes from a study demonstrating that blocking nAChRs in the VTA decreases 
NAc DA release stimulated by systemic nicotine (Nisell et al. 1994a).    
 The finding that the sensitivity of mesoaccumbens DA projections to local 
nicotine infusions is enhanced following adolescent nicotine exposure is in line 
with previous work demonstrating that nicotine exposure during adolescence can 
result in changes in brain regions associated with nicotine reinforcement and 
dependence.  This will be discussed, together with the results of the third aim of 
this dissertation, later in this section.   
 To summarize thus far, these data demonstrate evidence for persistent 
sensitization of the dopaminergic projections from the VTA to the shell of the NAc 
in adult rats as a result of prior exposure to nicotine during adolescence.  In 
response to a series of intra-VTA miroinjections of nicotine, the increase of DA in 
the NAc is enhanced in rats with adolescent nicotine exposure.  While only the 
no-net-flux technique of microdialysis can obtain true quantitative measures of 
extracellular DA, the traditional microdialysis procedure was successfully used 
here to demonstrate clear percent increases in extracellular DA amounts in the 
NAc compared to baseline levels within individual animals.  Further studies using 
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the no-net-flux technique should be conducted to explore quantitatively whether 
adolescent nicotine exposure affects baseline extracellular DA levels within the 
NAc. 
Next, the persistent effects of adolescent nicotine exposure on behavioral 
sensitization to nicotine were investigated.  The primary finding of the third part of 
this dissertation is that adolescent nicotine exposure results in enhanced 
behavioral sensitization to the locomotor-increasing properties of nicotine during 
adulthood in a dose-dependant manner.  Following the initial adulthood nicotine 
injection (Fig. 10), rats treated with nicotine during adolescence showed an 
enhanced locomotor response compared to those that were previously nicotine-
naïve.  Compared with the adolescent nicotine-naïve group, adolescent nicotine-
treated rats showed an accentuated increase in daily total activity levels across 
the 10 test sessions (Fig. 11).  Furthermore, these elevated activity levels 
persisted longer within each 1-hr test session in adolescent nicotine-treated rats 
than in saline controls, and this tendency strengthened across days (Figs. 12-
14).  These findings suggest that nicotine exposure during adolescence yields 
persistent changes in the neurobiological substrates underlying nicotine-induced 
behavioral sensitization. 
In rats treated with saline during adolescence, there was a modest effect 
of nicotine on LMA across the 10 test sessions (Fig. 11, top panel).  Previous 
studies indicated a more robust development of nicotine locomotor sensitization 
during adulthood in nicotine-naïve rats (Clarke and Kumar 1983a,b; Clarke et al. 
1988; Faraday et al. 2003).  Detailed temporal analysis of the data did indicate 
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significant nicotine-induced LMA increases in rats treated with saline during 
adolescence (Figs. 12-14, top panels).  However, the more modest effects of 
nicotine on LMA reported in the present study could also be the result of 
differences in rat species, or the lesser drug exposure paradigm used in the 
present study compared to previous studies (Berg and Chambers 2008). 
Nicotine treatment during adolescence resulted in elevated locomotion 
during the 1 hr of pre-injection activity recording that took place immediately 
before the first adulthood injection (Figs. 9 and 10).  Since this was the rats’ first 
experience in the activity chambers, these data reflect an elevation in response 
to a novel environment in the rats with adolescent history of nicotine treatment, 
suggesting persistent alterations in circuits regulating novelty-seeking behavior.  
The present findings are consistent with observations from previous research 
(Adriani et al. 2006). 
Adolescent nicotine treatment also resulted in differences in LMA induced 
by the first nicotine injection during adulthood.  As seen in Fig. 10, both of the 
adolescent nicotine exposures resulted in significantly higher activity in response 
to the initial adulthood dose of 0.25 mg/kg or 0.5 mg/kg nicotine.  These data 
indicate that adolescent nicotine exposure resulted in a long-lasting elevation in 
response to the stimulating effects of nicotine, which might reflect enhanced 
sensitivity to the reinforcing effects of nicotine. If nicotine exposure during 
adolescence had similar effect in humans, then increased sensitivity to the 
reinforcing effects of nicotine would likely promote smoking in adulthood.  
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In contrast to the adolescent saline-treated rats, rats that received nicotine 
(0.25 or 0.5 mg/kg) during adolescence showed significant overall effects and 
dose-dependent enhancements of sensitization to the locomotor-activating 
properties of nicotine.  The increases of daily LMA levels were more robust and 
appeared earlier in the 10-day study in the rats that had received 0.5 mg/kg 
nicotine during adolescence (Fig. 11, bottom panel) than those that had received 
0.25 mg/kg nicotine (Fig. 11, middle panel).  Not only were there differences in 
total daily distances traveled, but when the temporal data were examined within 
each locomotor session, the elevated LMA in response to daily nicotine injections 
persisted longer into each 60-minute session on successive days (Figs. 12-14).  
The observation that nicotine-induced behavioral sensitization was both 
increased across sessions and prolonged within sessions may shed light on the 
underlying neurobiological changes produced by the adolescent nicotine 
pretreatment. 
A working hypothesis in our laboratory is that drug exposure during 
adolescence results in long-lasting changes in sensitivity to drugs of abuse, 
which increases the propensity to use and/or abuse drugs during adulthood.  
This hypothesis applies to both the second and third aims of this dissertation.  
The results discussed above are supported by the literature.  Adolescents have 
shown differential responses to nicotine when compared with adults in studies of 
conditioned place preference (Vastola et al. 2002; Beluzzi et al. 2004) and 
behavioral sensitization (Faraday et al. 2003; Adriani et al. 2006).  Given the 
results of the second aim of this dissertation, demonstrating increased sensitivity 
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of the mesolimbic DA system to nicotine following prior nicotine exposure during 
adolescence, it is plausible that that same system underlies the observed 
increases in behavioral sensitization in the third aim.  The results of these two 
studies are very consistent with each other, especially in regards to the temporal 
nature of the increased nicotine sensitivity.  In both studies, response to nicotine 
(measured by NAc DA release or behavioral response to nicotine) was not only 
elevated in amplitude, but also increased in duration.  NAc DA was increased 
above baseline levels for twice as long in adolescent nicotine-treated rats as 
adolescent saline-treated rats, and similarly, adolescent nicotine-treated rats 
showed elevated locomotor activity longer into each locomotor recording session 
than adolescent saline-treated rats.  So while nicotine administration yielded 
significant responses in all groups in these two studies, the responses were both 
amplified and prolonged in the rats with an adolescent nicotine history. 
Previous work lends support to the hypothesis that adolescent drug 
exposure can increase sensitivity to drugs later in life.  Indeed, in humans, data 
indicate that adolescent smoking increases the risk of later dependence on 
nicotine as well as other drugs (Yamaguchi and Kandel 1984).  Previous work 
showed that rats that consumed EtOH during adolescence showed increased 
acquisition of operant EtOH self-administration, resistance to extinction, and 
susceptibility to relapse during adulthood (Rodd-Henricks et al. 2002).  Also, it 
has been shown that adolescent EtOH consumption by alcohol-preferring (P) rats 
increases both basal and EtOH-induced mesolimbic dopamine 
neurotransmission in adults (Sahr et al. 2004).  These findings all support the 
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hypothesis that drug exposure during adolescence can result in persistent 
changes in sensitivity to certain behavioral effects of drugs, and that alterations in 
sensitivity are dependent on changes within the mesolimbic DA system.  Given 
that the mesolimbic DA system has been shown to underlie the locomotor 
stimulant action of nicotine (Clarke et al. 1988), the same principles likely apply 
to the current studies discussed here. 
Previous research has indicated that many neurobiological changes may 
take place following adolescent exposure to nicotine.  For example, nAChRs in 
several brain areas, including the midbrain, were upregulated to a greater and 
more persistent extent in adolescent rats treated with nicotine than in adult rats 
that received similar nicotine exposure (Trauth et al. 1999; Adriani et al. 2003).  It 
is clear that the density of nAChRs in various brain regions, especially the 
midbrain, could influence the way the mesolimbic DA system reacts to a nicotine 
challenge and therefore the locomotor activity which it mediates.  Adolescent 
nicotine exposure has also been shown to reduce DA transporter densities in the 
striatum, including the NAc (Collins et al. 2004b).  Reductions in DA transporter 
density could decrease DA reuptake and thereby increase the amount of DA in 
the synapse, which could in turn increase the response of the system as a whole 
to nicotine.  However, the extracellular DA increases observed in the current 
study are more likely due to increased DA release rather than decreased 
reuptake, given the observation that DA clearance in the NAc is actually 
increased by nicotine, rather than decreased (Ksir et al. 1995).    
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The previous findings that nAChR levels are up-regulated in the midbrain, 
including the VTA, in adult rats following adolescent treatment with nicotine may 
underlie the observations in the current studies.  Higher levels of nAChRs in the 
VTA could result in the observed increase in neurobiological and behavioral 
sensitivity to nicotine, as a function of stronger activation of dopaminergic 
projections in response to systemic nicotine injections.   
To summarize the second and third parts of this dissertation, adolescent 
nicotine exposure results in enhanced sensitivity to the effects of nicotine during 
adulthood, suggesting that nicotine exposure during adolescence can result in 
persistent changes in the mesolimbic DA system and the behaviors that it 
mediates.  This is an indication that adolescent nicotine exposure may cause 
enhanced vulnerability to the reinforcing effects of nicotine and promote smoking 
in humans. 
 
C.  Adolescent nicotine exposure enhances adulthood EtOH drinking in Wistar 
and P rats 
 
 After identifying long-lasting changes in the mesolimbic DA system and a 
behavior mediated by that system as a result of nicotine exposure during 
adolescence, the final step was to assess the influence of adolescent nicotine 
exposure on subsequent drug-taking behavior.  Since nicotine and EtOH are so 
widely co-abused in human populations, EtOH drinking behavior was used as the 
behavioral measure for this study. 
 116 
The fourth part of this dissertation presents the primary finding that 
nicotine exposure during adolescence enhances subsequent EtOH intake during 
adulthood in both Wistar and alcohol-preferring P rats (Figs. 16 and 18).  In rats 
with access to 5% and 10% EtOH solutions, EtOH intake during the continuous 
access phase of the experiment was significantly increased in adults that were 
exposed to the higher (0.5 mg/kg) nicotine dose during adolescence, as 
compared to nicotine-naïve rats.  In the case of the Wistar rats, the elevated 
EtOH intake was apparent during the acquisition phase of EtOH drinking; that is, 
the initial 4 weeks of the 8-week continuous EtOH access period (Fig. 16).  For 
the P rats with access to 5% and 10% EtOH, the elevated EtOH intake was 
observed across all 8 weeks of continuous EtOH access (Fig. 18).  This 
difference in the pattern of enhancement of EtOH intake may indicate that the 
adolescent nicotine exposure had a more prolonged effect in the P rats, such that 
the effects on EtOH intake persisted through all weeks of continuous EtOH 
access.  In Wistar rats that were exposed to nicotine as adults, no differences in 
subsequent EtOH intake were observed (Fig. 34).  Together, these findings 
suggest that exposure to nicotine during adolescence yields persistent changes 
in the neurobiological substrates underlying EtOH drinking, both in a non-
selected rat line and in rats selectively bred for EtOH preference.   
 Although nicotine-related changes in EtOH intake over the 8-week 
continuous access period were observed, there were no effects of adolescent 
nicotine treatment on EtOH intake during the initial 7 days of access for either 
Wistar or P rats (Fig. 15).  Whereas the three groups of rats (Wistars, P rats 
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drinking lower EtOH concentrations, and P rats drinking higher EtOH 
concentrations) demonstrated markedly different EtOH intake levels even on the 
first day of EtOH access (approximately 2-4 g/kg, 6-7 g/kg, and 8-10 g/kg, 
respectively), adolescent nicotine exposure had no effects on EtOH intake during 
this first week. 
 It is interesting to note that adolescent nicotine exposure resulted in 
changes in EtOH preference in the P rats but not in the Wistar rats.  In the Wistar 
rats, there were no significant effects of adolescent nicotine treatment on 
preference for either 5%, 10%, or total EtOH (Fig. 17).  In the P rats, however, 
the elevation in EtOH intake by the 0.5 mg/kg nicotine-treated rats was 
predicated on a higher preference for 5% EtOH as well as total EtOH as a 
percentage of total fluid intake (Fig. 19).  These rats were consuming EtOH 
solutions for approximately 90% of their total fluid intake, whereas the 0.25 mg/kg 
nicotine and saline groups were consuming EtOH solutions for under 80% of 
their total fluid intake (Fig. 19, bottom panel).  This indicates that the underlying 
changes induced by adolescent nicotine exposure may result in increased 
preference for EtOH.  Since this effect was only observed in rats selectively bred 
for high EtOH preference, this lends support to the idea that the reinforcing 
actions of nicotine and EtOH may neurobiologically related and/or influenced by 
some common genes. 
 P rats were first tested in this study with access to the same EtOH 
concentrations as the Wistar rats, 5% and 10% EtOH.  This was done to allow for 
direct comparison between the rat strains, without needing to account for 
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differences in EtOH intake as a percentage of total fluid intake.  However, the 
EtOH intake levels achieved by this cohort of P rats did not quite reach those 
observed in previous studies, especially during the EtOH deprivation and 
reinstatement cycles (Rodd-Henricks et al. 2000c and 2001; Bell et al. 2008).  
Thus, a separate cohort of P rats received the same adolescent treatment as the 
previous groups, only this time given access to 15% and 30% EtOH during 
adulthood.  Although overall EtOH intake levels by these P rats were higher than 
in the previous group of P rats (8-9 g/kg/day vs. 5-6 g/kg/day), adolescent 
nicotine exposure did not have an effect on either the acquisition (first 4 weeks) 
or maintenance (second 4 weeks) phases of EtOH drinking in these rats (Fig. 
20).  Similarly, there were also no significant effects of adolescent nicotine 
exposure on preference for 15%, 30%, or total EtOH in these P rats (Fig. 21).  
Together, these results indicate that the effects of adolescent nicotine exposure 
on the neurocircuitry regulating EtOH drinking may be masked when EtOH 
consumption levels are high. 
 Another finding of this study is that nicotine exposure during adolescence 
did not have an effect on the expression of an alcohol deprivation effect (ADE) in 
any of the cohorts of rats.  The ADE is defined as a temporary increase in EtOH 
preference over baseline drinking conditions, when EtOH is reinstated following a 
period of deprivation (Sinclair and Senter 1967).  It has been proposed as a 
model of relapse-like drinking and, in animals, is considered to be a model of 
alcohol craving (Sinclair and Li 1989).  The expression of the ADE can be 
influenced by the length of EtOH deprivation and also by repeated deprivations 
 119 
(Rodd-Henricks et al. 2000b and 2000c).  The ADE was investigated here to 
determine whether adolescent exposure to nicotine might influence EtOH craving 
as indicated by elevated relapse-like drinking.  Although an ADE was seen in all 
cohorts of rats (Wistar and P rats drinking both the lower and higher EtOH 
concentrations), there were no differences among adolescent treatment groups 
in g/kg EtOH consumed during the reinstatement days.  Wistar rats showed a 
more prolonged ADE than either group of P rats, with elevated EtOH drinking 
levels persisting for the first 3 re-exposure days (Fig. 22).  In both groups of P 
rats, while significant increases above baseline EtOH drinking levels were 
observed, these increases only lasted for the first re-exposure day (Figs. 26 and 
30).  Taken together with the other results of this study, this finding indicates that 
the neurobiological substrates regulating relapse-like EtOH drinking behavior 
may be distinct from those regulating acquisition and maintenance of EtOH 
drinking, since acquisition of EtOH drinking was affected by adolescent nicotine 
exposure, whereas relapse EtOH drinking was not. 
 Interestingly, the post-deprivation increase in EtOH intake in P rats 
drinking 5% and 10% EtOH was modest (approximately 1 g/kg/day increase), 
which is consistent with a previous study from our laboratory showing only a 
modest ADE in P rats (Rodd-Henricks et al. 2000c; Bell et al. 2008), whereas the 
observed increase in EtOH intake in the P rats drinking 15% and 30% EtOH was 
much higher (approximately 3.5 g/kg/day increase).   
 When data from the three cycles of repeated EtOH deprivation and 
reinstatement were analyzed for EtOH preference, some interesting results 
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emerged.  In the Wistar rats, no effects of adolescent nicotine treatment were 
observed in EtOH preference following the first EtOH deprivation (Fig. 23).  
However, following the second EtOH deprivation, there was a significant Day x 
Adolescent Treatment interaction for both 5% and 10% EtOH preference (Fig. 
24, top and middle panels).  Interestingly, the rats in both adolescent nicotine 
groups showed an elevated preference for the lower EtOH concentration (5%) 
and a lower preference for the higher EtOH concentration (10%) compared with 
the adolescent saline-treated rats.  Following the third EtOH deprivation, the 
enhanced preference for 5% EtOH continued in the adolescent nicotine-treated 
rats (Fig. 25, middle panel).  This seems contradictory to the results reported 
earlier, indicating that adolescent nicotine treatment enhances EtOH intake 
during adulthood.  It is also contradictory to earlier work showing that rats shifted 
their preference from lower to higher concentrations following multiple EtOH 
deprivations (Rodd et al. 2009), although in that case, high-alcohol-drinking 
(HAD) rats were used, and drawing comparisons between selected and non-
selected lines is difficult.  However, it is possible that the increased overall EtOH 
consumption demonstrated by adolescent nicotine-treated Wistar rats is due to 
enhanced sensitivity to EtOH, which may result in those rats preferring the lower 
EtOH concentration compared to adolescent saline-treated rats.  If so, it appears 
that this effect is only apparent in the relapse-like conditions brought on by 
repeated EtOH deprivations. 
 Analysis of the EtOH preference data for the cohort of P rats drinking 5% 
and 10% EtOH also revealed significant effects of adolescent nicotine exposure.  
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Following the first EtOH deprivation, the significant main effect of adolescent 
nicotine treatment on preference for both 5% and 10% EtOH was the result of the 
adolescent nicotine-treated rats (particularly the 0.5 mg/kg nicotine dose) 
showing a greater preference for 5% EtOH and a lower preference for 10% EtOH 
(Fig. 27, top and middle panels).  This mirrored the effect observed in the Wistar 
rats.  However, there were no significant effects of adolescent nicotine exposure 
on EtOH preference following the second and third periods of EtOH deprivation 
(Figs. 28 and 29), so in the case of the P rats, the effect was not brought out by 
repeated EtOH deprivations. 
 Adolescent nicotine exposure had no significant effects on EtOH 
preference under relapse-like drinking conditions in the cohort of P rats drinking 
the higher concentrations (15% and 30%) of EtOH (Figs. 31-33).  This is 
consistent with the earlier conclusion that the effects of adolescent nicotine 
exposure on the neurocircuitry regulating EtOH drinking, and in this case EtOH 
preference, may be masked when EtOH intake levels are high. 
 It is a widely held hypothesis that drug exposure during adolescence 
results in persistent changes in sensitivity to drugs of abuse, which increases the 
likelihood of drug use and/or abuse in adulthood.  The results of previous 
sections of this dissertation have lent support to this hypothesis.  It has been 
shown that adolescent EtOH consumption in P rats yields changes in adulthood 
EtOH self-administration including increased acquisition of operant responding 
for EtOH and susceptibility to relapse following extinction training (Rodd-Henricks 
et al. 2002).  Previous work has also linked adolescent nicotine exposure to an 
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increased propensity for adulthood nicotine self-administration in rats (Adriani et 
al. 2003).  Additionally, chronic nicotine exposure, while not necessarily during 
adolescence, has been shown to result in subsequent increases in EtOH 
consumption (Blomqvist et al. 1996; Le et al. 2000; Clark et al. 2001).  The 
current study adds an important element to the literature by showing that nicotine 
exposure during adolescence can result in a persistent enhancement in the 
acquisition of EtOH drinking behavior during adulthood.  The fact that this effect 
seems to be prolonged in P rats compared to Wistar rats is supported by the 
previous findings that P rats are more sensitive to certain effects of nicotine 
(Gordon et al. 1993; Le et al. 2006). 
 Two previous studies have investigated the effects of adolescent nicotine 
exposure on subsequent EtOH drinking, which were described in the 
Introduction.  To review briefly, one study concluded that adulthood EtOH 
drinking was not affected by peri-adolescent nicotine exposure (Smith et al. 
2002).  However, several important differences exist between that study and the 
current one.  First, nicotine exposure (PD 35-56) extended beyond the 
adolescent timeframe and overlapped with the start of EtOH access.  The 
method of nicotine exposure also differs between that study and the current one.  
Smith and colleagues used a subcutaneous 21-day time-release pellet containing 
a specific dose of nicotine, versus the daily nicotine injections (intermittent 
exposure) given in the current study.  Additionally, EtOH intake was only 
measured for 21 days, which may not have been long enough for nicotine-
induced changes in drinking behavior to be observed.  Finally, the previous study 
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used female Sprague-Dawley rats, and the current study uses male Wistar and P 
rats, so strain and gender differences could play a role in divergent results. 
 A second, more recent published study used alcohol-preferring AA rats to 
study the effects of adolescent nicotine exposure on adulthood EtOH intake 
(Kemppainen et al. 2009).  That study also concluded that adulthood EtOH intake 
was unaffected by adolescent nicotine exposure.  Continuous access to 10% 
EtOH (in addition to water) commenced on PD 93 and lasted for four weeks.  No 
differences among adolescent treatment groups (nicotine or saline) were 
observed.  This could have been due to the single concentration of EtOH, as rats 
drink higher overall amounts of EtOH when given access to multiple EtOH 
concentrations.  Again, the duration of the EtOH drinking study was much shorter 
than the study in this dissertation, at only 28 days.  Thus, it may have been to 
short of a study to observe differences in EtOH drinking behavior between 
adolescent treatment groups.  Additionally, although AA rats were selectively 
bred from Wistar rats, there could be genetic differences between AA rats and 
the Wistar and P rats used in the current study, which confer divergent 
responses to adolescent nicotine exposure.   
As mentioned earlier, previous work has demonstrated that nicotinic 
cholinergic receptor (nAChR) levels are up-regulated in the midbrain, including 
the ventral tegmental area (VTA), in adult rats following adolescent treatment 
with nicotine (Trauth et al. 1999; Abreu-Villaca et al. 2003; Adriani et al. 2003).  
The VTA is an essential neural substrate for EtOH self-administration, as 
evidenced studies demonstrating intracranial self-administration of EtOH into the 
 124 
pVTA but not areas surrounding the pVTA in Wistar rats (Rodd-Henricks et al. 
2000a).  Studies have also shown indicated a role for VTA DA activity in EtOH 
consumption both by operant and free-choice drinking means, as activation of 
inhibitory D2 receptors decreased EtOH intake (Hodge et al. 1996; Nowak et al. 
2000).  Up-regulated nAChR levels in the VTA may play a role in the observed 
enhancement in EtOH drinking by adolescent nicotine-treated rats, not just 
because of their location at a site demonstrated here to be involved in adolescent 
nicotine-induced changes in responses to adulthood nicotine, but because 
previous research has implicated nAChRs for a role in EtOH stimulation of the 
mesolimbic DA system.  Additionally, this dissertation has revealed that the pVTA 
is also a site at which nicotine stimulates NAc DA release and supports self-
administration. 
Together, these results provide support for a role for nAChRs in EtOH 
consumption.  Considering the results presented in this section, it is plausible 
that adolescent nicotine exposure results in long-lasting changes in nAChRs in 
brain areas regulating EtOH drinking behavior.  Nicotinic mechanisms may also 
underlie the expression of an ADE, given that adolescent-nicotine-induced 
changes in preference for different EtOH concentrations were observed following 
periods of EtOH deprivation. 
 In summary, adolescent exposure to nicotine enhances acquisition of 
EtOH drinking behavior during adulthood in Wistar rats and in P rats with access 
to lower concentrations of EtOH.  This effect was masked in P rats when EtOH 
intake levels were higher, and effects on the ADE were limited to changes in 
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preference between multiple EtOH concentrations rather than total EtOH intake.  
This suggests that nicotine exposure during adolescence can result in persistent 
changes in the neurobiological substrates regulating EtOH drinking behavior and 
EtOH preference, which indicates that teenage smoking may promote 
subsequent alcohol drinking in humans. 
 
D.  Other possible mechanisms by which adolescent nicotine exposure could 
influence adulthood neurobiology and behavior 
 
 Due to the complex and widespread actions of nicotine in the brain, and 
the wide scope of neurological changes that the developing adolescent brain 
undergoes, the number of possible mechanisms underlying the persistent effects 
of adolescent nicotine demonstrated here are virtually limitless.  In the previous 
sections, nAChRs have been focused on as a likely substrate for the observed 
changes in adulthood measures following nicotine treatment during adolescence, 
due to the strong support from the literature for their involvement in all of the 
endpoints studied.  However, there are many other possible mechanisms by 
which adolescent nicotine treatment could exert its lasting effects. 
Other neurotransmitters in addition to DA are likely involved in the 
development and expression of the observed sensitization to nicotine.  For 
example, studies have indicated that excitatory amino acids are also involved in 
behavioral sensitization to psychomotor stimulants (reviewed by Kalivas, 1995).  
Recall also the mechanism of nAChR activation and desensitization within the 
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VTA proposed by Mansvelder and McGehee (2002) and discussed earlier in this 
dissertation, wherein both glutamate and GABA are implicated to play a role in 
long-lasting nicotine stimulation of VTA DA projections.  Other studies have 
demonstrated that stimulating VTA or NAc shell metabotropic glutamate 2/3 
(mGlu2/3) receptors, which are presynaptic and therefore inhibit glutamate 
transmission when activated, decreased i.v. nicotine self-administration (Liechti 
et al. 2007).  Nicotine self-administration has also been shown to up-regulate 
NMDA receptor subunit expression in the VTA (Kenny et al. 2009).  Based on 
these collective findings, it is possible that DA and excitatory and inhibitory amino 
acids are all involved in the up-regulated responses to nicotine in adolescent 
nicotine-treated animals observed in the current studies as part of a complex 
mechanism. 
Serotonin is another neurotransmitter system that may be involved in the 
long-lasting effects of adolescent nicotine exposure.  Serotonin transporter 
densities in the striatum were reduced following repeated nicotine administration, 
both acutely and in a persistent fashion (Collins et al. 2004b; Xu et al. 2001).  
This could lead to increased levels of serotonin within the synapse and therefore 
enhanced serotonergic input at postsynaptic sites.  In a more recent study, 
nicotine was administered throughout gestation in rats, and then the responses 
of serotonin receptors and transporters to adulthood nicotine treatment were 
studied (Slotkin et al. 2007).  Prenatal exposure to nicotine effectively 
reprogrammed the way the serotonergic system responded to nicotine, resulting 
in differing up- and down-regulation of specific serotonin receptor subtypes.  
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Although the nicotine pre-exposure in this case was during gestation rather than 
adolescence, the previous study demonstrates the vulnerability of a developing 
system to persistent drug-induced changes.  
The mu opioid system has also been implicated in nicotine self-
administration behaviors.  Mu opioid receptors are located in the VTA, primarily 
on GABA interneurons and on feedback projections from the NAc (Kalivas 1993).  
The effects of intra-VTA infusion of the mu opioid agonist DAMGO, as well as the 
GABAA agonist muscimol and the GABAB agonist baclofen, were tested on i.v. 
self-administration of nicotine (Corrigall et al. 2000).  DAMGO only attenuated 
nicotine self-administration at the highest dose, in contrast to both GABA 
agonists, which showed a much more pronounced decrease of nicotine self-
administration.  So, while mu opioid receptors may be involved in nicotine self-
administration, it is likely via a more indirect mechanism than disinhibition of the 
VTA DA neurons by interfering with local GABA interneuron signaling.  
Alternatively, nicotine itself might reduce the amount of GABA signaling in the 
VTA, rendering mu opioid activity less able to result in disinhibition of the VTA DA 
neurons.  It is possible that adolescent nicotine exposure could alter the way mu 
opioid and/or GABA receptors function to recruit GABAergic feedback to the 
VTA.  This is an example of yet another neurotransmitter system with complex 
involvement in nicotine reinforcement.   
Even more basic intracellular signaling molecules have been altered by 
adolescent nicotine exposure.  Adenylyl cyclase (AC) activity was studied in 
response to adulthood nicotine administration, and numerous alterations in the 
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signaling cascade were observed, in brain areas including the cerebral cortex 
and brainstem, in rats exposed to nicotine during adolescence compared to 
nicotine-naïve rats (Slotkin et al. 2008).  Both basal and nicotine-induced AC 
activity were affected, although sometimes differently between males and 
females.  Clearly, exposure to nicotine during the vulnerable adolescent time 
period can result in a myriad of complex changes throughout the brain, many of 
which may influence various responses to nicotine later in life. 
 One or more of these systems could be impacted in adulthood by changes 
in gene expression triggered by nicotine during adolescence.  Recently, 
microarray technology is beginning to be used to identify genes whose 
expression is altered by nicotine.  One such study investigated nicotine’s effects 
on genes specifically during the adolescent timeframe (Polesskaya et al. 2007).  
Nicotine was administered continuously via osmotic minipumps, and gene 
expression in different brain areas was assessed at four different time points: PD 
25 (just prior to adolescence), PD 35 (during adolescence), PD 45 (post-
adolescence), and PD 55 (early adulthood).  Genes whose expression was 
changed regulated everything from cell metabolism to signal transduction to 
vesicular trafficking, but the overall conclusion was that the majority of the genes 
studied showed dramatic peaks in nicotine responses at the PD 35 time point.  
These results were consistent with the behavioral literature showing that 
adolescent rodents are particularly vulnerable to nicotine’s effects.  Clearly, there 
is much more research to be done into the gene expression changes influenced 
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by adolescent nicotine, as this could represent the underpinnings of so many of 
the persistent effects mentioned here. 
 
E.  Summary and future directions  
 
 The objectives of this dissertation were to 1) determine whether nicotine 
would be self-administered into the posterior pVTA, a neuroanatomical 
component of the mesolimbic DA system, which is known to be involved in 
reward and reinforcement; 2) investigate whether adolescent nicotine exposure 
would alter the sensitivity of the mesolimbic DA system as measured by DA 
release in the NAc in response to nicotine microinjections into the pVTA; 3) 
examine the effects of adolescent nicotine exposure on behavioral sensitization 
to nicotine in adulthood; and 4) investigate whether adulthood alcohol drinking 
behavior, in both Wistar and P rats, would be augmented by nicotine exposure 
during adolescence.  The results of this dissertation have demonstrated that 1) 
the pVTA is a neuroanatomical site that supports nicotine self-administration; and 
that adolescent nicotine exposure results in 2) increased nicotine-stimulated DA 
release in the NAc during adulthood; 3) augmented behavioral sensitization to 
nicotine in adult animals; and 4) enhanced acquisition of alcohol drinking 
behavior in adult Wistar and P rats.  
 The results of this dissertation provide insight into the persistent changes, 
on both neurobiology and behavior, caused by exposure to nicotine during the 
critical developmental period of adolescence.  While nicotine has complex effects 
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throughout many brain regions, one consistent theme identified here is the likely 
involvement of nAChRs in the neurobiological and behavioral effects that were 
observed.  It is plausible that nicotine administered during adolescence alters the 
functionality of nAChRs in brain regions important for drug reinforcement in such 
a way as to increase sensitivity to subsequent drug exposure during adulthood.   
Clearly, much future research is necessary to determine the specific 
effects on nAChRs and the mesolimbic DA system, and also what other 
receptors and systems might be involved.  With a better understanding of the 
changes that take place in the brain following adolescent drug exposure, it may 
become possible to more successfully treat or even prevent subsequent drug 
addictions in people whose first experience with substances of abuse came 
during the critical adolescent window. 
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